Адаптована клінічна настанова, заснована на доказах, Акне. Список літератури

Адаптована клінічна настанова, заснована на доказах, Акне

СПИСОК ЛІТЕРАТУРИ

European Evidence-based (S3) Guidelines for the Treatment of Acne. European Dermatology Forum. 2011

1 Field M, Lohr KN. Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines. Clinical Practice Guidelines: Directions for a New Program. National Academy Press, Washington, DC, 1990.

2 Cunliffe WJ. The Acnes. Martin Dunitz Ltd, London, 1989.

3 Cunliffe WJ, Shuster S. Pathogenesis of acne. Lancet 1969; 1: 685–687.

4 Lucky AW, Biro FM, Huster GA, Leach AD, Morrison JA, Ratterman J. Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol 1994; 130: 308–314.

5 Burke BM, Cunliffe WJ. The assessment of acne vulgaris – the Leeds technique. Br J Dermatol 1984; 111: 83–92.

6 Orentreich N, Durr NP. The natural evolution of comedones into inflammatory papules and pustules. J Invest Dermatol 1974; 62: 316–320.

7 Lehmann HP, Robinson KA, Andrews JS, Holloway V, Goodman SN. Acne therapy: a methodologic review. J Am Acad Dermatol 2002; 47: 231–240.

8 Barratt H, Hamilton F, Car J, Lyons C, Layton A, Majeed A. Outcome measures in acne vulgaris: systematic review. Br J Dermatol 2009; 160: 132–136.

9 Witkowski JA, Parish LC. The assessment of acne: an evaluation of grading and lesion counting in the measurement of acne. Clin Dermatol 2004; 22: 394–397.

10 Thiboutot D, Gollnick H, Bettoli V et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009; 60: S1–S50.

11 Gollnick H, Cunliffe WJ, Berson D et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49: S1–S37.

12 Gollnick HPM, Finlay AY, Shear N. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol 2008; 9: 279–284.

13 O’brien SC, Lewis JB, Cunliffe WJ. The Leeds revised acne grading system. J Dermatolog Treat 1998; 9: 215–220.

14 Dreno B, Bodokh I, Chivot M et al. [ECLA grading: a system of acne classification for every day dermatological practice]. Ann Dermatol Venereol 1999; 126: 136–141.

15 Dreno B, Alirezai M, Auffret N et al. [Clinical and psychological correlation in acne: use of the ECLA and CADI scales]. Ann Dermatol Venereol 2007; 134: 451–455.

16 Pochi PE, Shalita AR, Strauss JS et al. Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24 and 25, 1990. J Am Acad Dermatol 1991; 24: 495–500.

17 Cook CH, Centner RL, Michaels SE. An acne grading method using photographic standards. Arch Dermatol 1979; 115: 571–575.

18 Pillsbury DM, Shelley WB, Kligman AM. Acne, acneform eruptions and rosacea. In Pillsbury DM, Shelley WB, Kligman AM, eds. Dermatology. Saunders, Philadelphia, 1956: 8004–8027.

19 Michaelsson G, Juhlin L, Vahlquist A. Effects of oral zinc and vitamin A in acne. Arch Dermatol 1977; 113: 31–36.

20 Wilson RG. Office application of a new acne grading system. Cutis 1980; 25: 62–64.

21 Allen BS, Smith JG Jr. Various parameters for grading acne vulgaris. Arch Dermatol 1982; 118: 23–25.

22 Layton AM. Disorders of the sebaceous glands. In Burns T, Breathnach S, Cosx N, Griffiths C, eds. Rook’s Textbook of Dermatology, 8th edn. Wiley-Blackwell, Oxford, 2010: 38–39.

23 Tan JK, Tang J, Fung K et al. Development and validation of a comprehensive acne severity scale. J Cutan Med Surg 2007; 11: 211–216.

24 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry. Acne vulgaris: developing drugs for treatment. 2005.

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/

Guidances/UCM071292.pdf (last accessed: 4 May 2011).

25 Simpson NB, Cunliffe WJ. Disorders of the sebaceous glands. In Burns T, Breathnach S, Cosx N, Griffiths C, eds. Rook’s Textbook of Dermatology, 7th edn. Blackwell Science, Oxford, 2004: 43.

26 Holland DB, Jeremy AH. The role of inflammation in the pathogenesisof acne and acne scarring. Semin Cutan Med Surg 2005; 24:79–83.

27 Dreno B, Bettoli V, Ochsendorf F et al. An expert view on the treatmentof acne with systemic antibiotics and ⁄ or oral isotretinoin in thelight of the new European recommendations. Eur J Dermatol 2006; 16:565–571.

28 Layton AM, Henderson CA, Cunliffe WJ. A clinical evaluation of acnescarring and its incidence. Clin Exp Dermatol 1994; 19: 303–308.

29 Pathirana D, Nast A, Ormerod AD et al. On the development of theEuropean S3 guidelines on the systemic treatment of psoriasis vulgaris:structure and challenges. J Eur Acad Dermatol Venereol 2010; 24:1458–1467.

30 Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines onthe systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol2009; 23(Suppl 2): 1–70.

31 GRADE working group. URL http://www.gradeworkinggroup.org/ (lastaccessed: 2 November 2010).

32 Amado JM, Matos ME, Abreu AM et al. The prevalence of acne in thenorth of Portugal. J Eur Acad Dermatol Venereol 2006; 20: 1287–1295.

33 Kilkenny M, Merlin K, Plunkett A, Marks R. The prevalence of commonskin conditions in Australian school students: 3. acne vulgaris. BrJ Dermatol 1998; 139: 840–845.

34 Nijsten T, Rombouts S, Lambert J. Acne is prevalent but use of itstreatments is infrequent among adolescents from the general population.J Eur Acad Dermatol Venereol 2007; 21: 163–168.

35 Smithard A, Glazebrook C, Williams HC. Acne prevalence, knowledgeabout acne and psychological morbidity in mid-adolescence: a community-based study. Br J Dermatol 2001; 145: 274–279.

36 Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults.J Am Acad Dermatol 1999; 41: 577–580.

37 Friedman GD. Twin studies of disease heritability based on medicalrecords: application to acne vulgaris. Acta Genet Med Gemellol (Roma).1984; 33: 487–495.

38 Dreno B, Poli F. Epidemiology of acne. Dermatology 2003; 206: 7–10.

39 Herane MI, Ando I. Acne in infancy and acne genetics. Dermatology2003; 206: 24–28.

40 Perkins A, Cheng C, Hillebrand G, Miyamoto K, Kimball A. Comparisonof the epidemiology of acne vulgaris among Caucasian, Asian,Continental Indian and African American women. J Eur Acad DermatolVenereol 2010; 25: 1054–1060.

41 Cheng CE, Irwin B, Mauriello D, Liang L, Pappert A, Kimball AB.Self-reported acne severity, treatment, and belief patterns across multipleracial and ethnic groups in adolescent students. Pediatr Dermatol2010; 27: 446–452.

42 Cordain L, Lindeberg S, Hurtado M, Hill K, Eaton SB, Brand-Miller J.Acne vulgaris: a disease of Western civilization. Arch Dermatol 2002;138: 1584–1590.

43 Adebamowo CA, Spiegelman D, Danby FW, Frazier AL, Willett WC,Holmes MD. High school dietary dairy intake and teenage acne. J AmAcad Dermatol 2005; 52: 207–214.

44 Smith RN, Mann NJ, Braue A, Makelainen H, Varigos GA. A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomizedcontrolled trial. Am J Clin Nutr 2007; 86: 107–115.

45 Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaicacid cream in the treatment of acne vulgaris. Comparison with vehicleand topical tretinoin. Acta Derm Venereol Suppl (Stockh) 1989; 143:35–39.

46 Iraji F, Sadeghinia A, Shahmoradi Z, Siadat AH, Jooya A. Efficacy oftopical azelaic acid gel in the treatment of mild-moderate acne vulgaris.Indian J Dermatol Venereol Leprol 2007; 73: 94–96.

47 Cunliffe WJ, Holland KT. Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Derm Venereol Suppl (Stockh) 1989; 143: 31–34.

48 Sklar JL, Jacobson C, Rizer R, Gans EH. Evaluation of Triaz 10% Gel and Benzamycin in acne vulgaris. J Dermatolog Treat 1996; 7: 147–152.

49 Hughes BR, Norris JF, Cunliffe WJ. A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clin Exp Dermatol 1992; 17: 165–168.

50 Thiboutot DM, Weiss J, Bucko A et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57: 791–799.

51 Gold LS, Tan J, Cruz-Santana A et al. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis 2009; 84: 110–116.

52 Papageorgiou PP, Chu AC. Chloroxylenol and zinc oxide containing cream (Nels cream) vs. 5% benzoyl peroxide cream in the treatment of acne vulgaris. A double-blind, randomized, controlled trial. Clin Exp Dermatol 2000; 25: 16–20.

53 Hunt MJ, Barnetson RS. A comparative study of gluconolactone versus benzoyl peroxide in the treatment of acne. Australas J Dermatol 1992; 33: 131–134.

54 Webster G, Rich P, Gold MH, Mraz S, Calvarese B, Chen D. Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. J Drugs Dermatol 2009; 8: 736–743.

55 Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008; 59: 792–800.

56 Lookingbill DP, Chalker DK, Lindholm JS et al. Treatment of acne with a combination clindamycin ⁄ benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997; 37: 590–595.

57 Tschen EH, Katz HI, Jones TM et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis 2001; 67: 165–169.

58 Fagundes DS, Fraser JM, Klauda HC. New therapy update – a unique combination formulation in the treatment of inflammatory acne. Cutis 2003; 72: 16–19.

59 Burke B, Eady EA, Cunliffe WJ. Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. Br J Dermatol 1983; 108: 199–204.

60 Gollnick HP, Draelos Z, Glenn MJ et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 2009; 161: 1180–1189.

61 Thiboutot D, Pariser DM, Egan N et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol 2006; 54: 242–250.

62 Pariser DM, Thiboutot DM, Clark SD, Jones TM, Liu Y, Graeber M. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: a randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis 2005; 76: 145–151.

63 Lucky A, Jorizzo JL, Rodriguez D et al. Efficacy and tolerance of adapalene cream 0.1% compared with its cream vehicle for the treatment of acne vulgaris. Cutis 2001; 68: 34–40.

64 Kawashima M, Harada S, Loesche C, Miyachi Y. Adapalene gel 0.1% is effective and safe for Japanese patients with acne vulgaris: a randomized, multicenter, investigator-blinded, controlled study. J Dermatol Sci 2008; 49: 241–248.

65 Chalker DK, Lesher JL Jr, Smith JG Jr et al. Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, doubleblind investigation. J Am Acad Dermatol 1987; 17: 251–254.

66 Glass D, Boorman GC, Stables GI, Cunliffe WJ, Goode K. A placebocontrolled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatology 1999; 199: 242–247.

67 Berger R, Barba A, Fleischer A et al. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults. Cutis 2007; 80: 152–157.

68 Christiansen J, Holm P, Reymann F. The retinoic acid derivative Ro 11-1430 in acne vulgaris. A controlled multicenter trial against retinoic acid. Dermatologica 1977; 154: 219–227.

69 Krishnan G. Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris. Practitioner 1976; 216: 106–109.

70 Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol 1998; 38: S17–S23.

71 Lucky AW, Cullen SI, Funicella T, Jarratt MT, Jones T, Reddick ME. Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol 1998; 38: S24–S30.

72 Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin ⁄ tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006; 54: 73–81.

73 Pedace FJ, Stoughton R. Topical retinoic acid in acne vulgaris. Br J Dermatol 1971; 84: 465–469.

74 Nighland M, Grossman R. Tretinoin microsphere gel in facial acne vulgaris: a meta-analysis. J Drugs Dermatol 2008; 7: s2–s8.

75 Webster G, Cargill DI, Quiring J, Vogelson CT, Slade HB. A combined analysis of 2 randomized clinical studies of tretinoin gel 0.05% for the treatment of acne. Cutis 2009; 83: 146–154.

76 Kuhlman DS, Callen JP. A comparison of clindamycin phosphate 1 percent topical lotion and placebo in the treatment of acne vulgaris. Cutis 1986; 38: 203–206.

77 Lucchina LC, Kollias N, Gillies R et al. Fluorescence photography in the evaluation of acne. J Am Acad Dermatol 1996; 35: 58–63.

78 Rizer RL, Sklar JL, Whiting D, Bucko A, Shavin J, Jarratt M. Clindamycin phosphate 1% gel in acne vulgaris. Adv Ther 2001; 18: 244–252.

79 Shalita AR, Myers JA, Krochmal L, Yaroshinsky A. The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris. J Drugs Dermatol 2005; 4: 48–56.

80 Blaney DJ, Cook CH. Topical use of tetracycline in the treatment of acne: a double-blind study comparing topical and oral tetracycline therapy and placebo. Arch Dermatol 1976; 112: 971–973.

81 Smith JG Jr, Chalker DK, Wehr RF. The effectiveness of topical and oral tetracycline for acne. South Med J 1976; 69: 695–697.

82 Mills O Jr, Thornsberry C, Cardin CW, Smiles KA, Leyden JJ. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002; 82: 260–265.

83 Dobson RL, Belknap BS. Topical erythromycin solution in acne. Results of a multiclinic trial. J Am Acad Dermatol 1980; 3: 478–482.

84 Llorca M, Hernandez-Gill A, Ramos M et al. Erythromycin laurilsulfate in the topical treatment of acne vulgaris. Curr Ther Res 1982; 32: 14–20.

85 Pochi PE, Bagatell FK, Ellis CN et al. Erythromycin 2 percent gel in the treatment of acne vulgaris. Cutis 1988; 41: 132–136.

86 Stinco G, Bragadin G, Trotter D, Pillon B, Patrone P. Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. J Eur Acad Dermatol Venereol 2007; 21: 320–325.

87 do Nascimento LV, Guedes AC, Magalhaes GM, de Faria FA, Guerra RM, de C Almeida F. Single-blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. J Dermatolog Treat 2003; 14: 166–171.

88 Korkut C, Piskin S. Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. J Dermatol 2005; 32: 169–173.

89 Bucknall JH, Murdoch PN. Comparison of tretinoin solution and benzoyl peroxide lotion in the treatment of acne vulgaris. Curr Med Res Opin 1977; 5: 266–268.

90 Handojo I. The combined use of topical benzoyl peroxide and tretinoin in the treatment of acne vulgaris. Int J Dermatol 1979; 18: 489–496.

91 Lyons RE. Comparative effectiveness of benzoyl peroxide and tretinoin in acne vulgaris. Int J Dermatol 1978; 17: 246–251.

92 Swinyer LJ, Baker MD, Swinyer TA, Mills OH Jr. A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris. Br J Dermatol 1988; 119: 615–622.

93 Tucker SB, Tausend R, Cochran R, Flannigan SA. Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. Br J Dermatol 1984; 110: 487–492.

94 Norris JF, Hughes BR, Basey AJ, Cunliffe WJ. A comparison of the effectiveness of topical tetracycline, benzoyl-peroxide gel and oral oxytetracycline in the treatment of acne. Clin Exp Dermatol 1991; 16: 31–33.

95 Gollnick HP, Graupe K, Zaumseil RP. [Azelaic acid 15% gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies]. J Dtsch Dermatol Ges 2004; 2: 841–847.

96 Rietschel RL, Duncan SH. Clindamycin phosphate used in combination with tretinoin in the treatment of acne. Int J Dermatol 1983; 22: 41–43.

97 Thiboutot D, Gold MH, Jarratt MT et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis 2001; 68: 10–19.

98 Tu P, Li GQ, Zhu XJ, Zheng J, Wong WZ. A comparison of adapalene gel 0.1% vs. tretinoin gel 0.025% in the treatment of acne vulgaris in China. J Eur Acad Dermatol Venereol 2001; 15(Suppl 3): 31–36.

99 Pierard-Franchimont C, Henry F, Fraiture AL, Fumal I, Pierard GE. Split-face clinical and bio-instrumental comparison of 0.1% adapalene and 0.05% tretinoin in facial acne. Dermatology 1999; 198: 218–222.

100 Cunliffe WJ, Danby FW, Dunlap F, Gold MH, Gratton D, Greenspan A. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol 2002; 12: 350–354.

101 Cunliffe WJ, Caputo R, Dreno B et al. Efficacy and safety comparison of adapalene (CD271) gel and tretinoin gel in the topical treatment of acne vulgaris. A European multicentre trial. J Dermatolog Treat 1997; 8: 173–178.

102 Ellis CN, Millikan LE, Smith EB et al. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris. Br J Dermatol 1998; 139(Suppl 52): 41–47.

103 Grosshans E, Marks R, Mascaro JM et al. Evaluation of clinical efficacyand safety of adapalene 0.1% gel versus tretinoin 0.025% gel in thetreatment of acne vulgaris, with particular reference to the onset ofaction and impact on quality of life. Br J Dermatol 1998; 139(Suppl52): 26–33.

104 Shalita A, Weiss JS, Chalker DK et al. A comparison of the efficacyand safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatmentof acne vulgaris: a multicenter trial. J Am Acad Dermatol 1996;34: 482–485.

105 Verschoore M, Langner A, Wolska H, Jablonska S, Czernielewski J, Schaefer H. Efficacy and safety of CD 271 alcoholic gels in the topical treatment of acne vulgaris. Br J Dermatol 1991; 124: 368–371.

106 Nyirady J, Grossman RM, Nighland M et al. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris. J Dermatolog Treat 2001; 12: 149–157.

107 Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J Dermatol 2002; 147: 523–527.

108 Dominguez J, Hojyo MT, Celayo JL, Dominguez-Soto L, Teixeira F. Topical isotretinoin vs. topical retinoic acid in the treatment of acne vulgaris. Int J Dermatol 1998; 37: 54–55.

109 Leyden JJ, Hickman JG, Jarratt MT, Stewart DM, Levy SF. The efficacy and safety of a combination benzoyl peroxide ⁄ clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide ⁄ erythromycin combination product. J Cutan Med Surg 2001; 5: 37–42.

110 Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, doubleblind comparison of a clindamycin phosphate ⁄ benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24: 1117–1133.

111 Kircik L, Green L, Thiboutot D et al. Comparing a novel solubilized benzoyl peroxide gel with benzoyl peroxide ⁄ clindamycin: final data from a multicenter, investigator-blind, randomized study. J Drugs Dermatol 2009; 8: 812–818.

112 Tanghetti E, Kircik L, Wilson D, Dhawan S. Solubilized benzoyl peroxide versus benzoyl peroxide ⁄ clindamycin in the treatment of moderate acne. J Drugs Dermatol 2008; 7: 534–538.

113 Zouboulis CC, Fischer TC, Wohlrab J, Barnard J, Alio AB. Study of the efficacy, tolerability, and safety of 2 fixed-dose combination gels in the management of acne vulgaris. Cutis 2009; 84: 223–229.

114 Tan J, Gollnick HP, Loesche C, Ma YM, Gold LS. Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients. J Dermatolog Treat 2010; 22: 197–205.

115 Gold LS, Cruz A, Eichenfield L et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixeddose combination gel with doxycycline hyclate 100 mg. Cutis 2010; 85: 94–104.

116 Kellett N, West F, Finlay AY. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial. Br J Dermatol 2006; 154: 524–532.

117 Henderson TA, Olson WH, Leach AD. A single-blind, randomized comparison of erythromycin pledgets and clindamycin lotion in the treatment of mild to moderate facial acne vulgaris. Adv Ther 1995; 12: 172–177.

118 Thielitz A, Helmdach M, Ro¨pke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 19–27.

119 Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol 2007; 21: 747–753.

120 Bernstein JE, Shalita AR. Topically applied erythromycin in inflammatory acne vulgaris. J Am Acad Dermatol 1980; 2: 318–321.

121 Hellgren L, Vincent J. Topical erythromycin for acne vulgaris. Dermatologica 1980; 161: 409–414.

122 Jones EL, Crumley AF. Topical erythromycin vs blank vehicle in a multiclinic acne study. Arch Dermatol 1981; 117: 551–553.

123 Lesher JL Jr, Chalker DK, Smith JG Jr et al. An evaluation of a 2% erythromycin ointment in the topical therapy of acne vulgaris. J Am Acad Dermatol 1985; 12: 526–531.

124 Prince RA, Busch DA, Hepler CD, Feldick HG. Clinical trial of topicalerythromycin in inflammatory acne. Drug Intell Clin Pharm 1981; 15:372–376.

125 Rivkin L, Rapaport M. Clinical evaluation of a new erythromycin solutionfor acne vulgaris. Cutis 1980; 25: 552–555.

126 Alirezai M, Gerlach B, Horvath A, Forsea D, Briantais P, GuyomarM. Results of a randomised, multicentre study comparing a newwater-based gel of clindamycin 1% versus clindamycin 1% topicalsolution in the treatment of acne vulgaris. Eur J Dermatol 2005; 15:274–278.

127 Braathen LR. Topical clindamycin versus oral tetracycline and placeboin acne vulgaris. Scand J Infect Dis Suppl 1984; 43: 71–75.

128 Gratton D, Raymond GP, Guertin-Larochelle S et al. Topical clindamycinversus systemic tetracycline in the treatment of acne. Results ofa multiclinic trial. J Am Acad Dermatol 1982; 7: 50–53.

129 Becker LE, Bergstresser PR, Whiting DA et al. Topical clindamycintherapy for acne vulgaris. A cooperative clinical study. Arch Dermatol1981; 117: 482–485.

130 Ellis CN, Gammon WR, Stone DZ, Heezen-Wehner JL. A comparisonof Cleocin T Solution, Cleocin T Gel, and placebo in the treatment ofacne vulgaris. Cutis 1988; 42: 245–247.

131 McKenzie MW, Beck DC, Popovich NG. Topical clindamycin formulationsfor the treatment of acne vulgaris. An evaluation. Arch Dermatol1981; 117: 630–634.

132 Petersen MJ, Krusinski PA, Krueger GG. Evaluation of 1% clindamycinphosphate lotion in the treatment of acne. Curr Ther Res 1986; 40:232–238.

133 Leyden JJ, Wortzman M. A novel gel formulation of clindamycinphosphate-tretinoin is not associated with acne flaring. Cutis 2008; 82:151–156.

134 Anderson RL, Cook CH, Smith DE. The effect of oral and topical tetracyclineon acne severity and on surface lipid composition. J InvestDermatol 1976; 66: 172–177.

135 Kurokawa I, Akamatsu H, Nishijima S, Asada Y, Kawabata S. Clinicaland bacteriologic evaluation of OPC-7251 in patients with acne: adouble-blind group comparison study versus cream base. J Am AcadDermatol 1991; 25: 674–681.

136 Ellis CN, Leyden J, Katz HI et al. Therapeutic studies with a new combinationbenzoyl peroxide ⁄ clindamycin topical gel in acne vulgaris.Cutis 2001; 67: 13–20.

137 Ede M. A double-blind, comparative study of benzoyl peroxide, benzoylperoxide-chlorhydroxyquinoline, benzoyl peroxide-chlorhydroxyquinoline-hydrocortisone, and placebo lotions in acne. Curr Ther ResClin Exp 1973; 15: 624–629.

138 Jaffe GV, Grimshaw JJ, Constad D. Benzoyl peroxide in the treatmentof acne vulgaris: a double-blind, multi-centre comparative study of‘Quinoderm’ cream and ‘Quinoderm’ cream with hydrocortisone versustheir base vehicle alone and a benzoyl peroxide only gel preparation.Curr Med Res Opin 1989; 11: 453–462.

139 Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%,and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol1986; 25: 664–667.

140 Smith EB, Padilla RS, McCabe JM, Becker LE. Benzoyl peroxide lotion(20 percent) in acne. Cutis 1980; 25: 90–92.

141 Langner A, Boorman GC, Stapor V. Isotretinoin cream 0.05% and0.1% in the treatment of acne vulgaris. J Dermatol Treat 1994; 5:177–180.

142 Webster GF. Safety and efficacy of Tretin-X compared with Retin-A inpatients with mild-to-severe acne vulgaris. Skinmed 2006; 5: 114–118.

143 Mills OH Jr, Kligman AM. Treatment of acne vulgaris with topicallyapplied erythromycin and tretinoin. Acta Derm Venereol 1978; 58:555–557.

144 Cavicchini S, Caputo R. Long-term treatment of acne with 20% azelaic145 Handojo I. Retinoic acid cream (Airol cream) and benzoyl-peroxide inthe treatment of acne vulgaris. Southeast Asian J Trop Med PublicHealth 1979; 10: 548–551.

146 Zhu XJ, Tu P, Zhen J, Duan YQ. Adapalene gel 0.1%: effective andwell tolerated in the topical treatment of acne vulgaris in Chinesepatients. Cutis 2001; 68: 55–59.

147 Leyden JJ, Berger RS, Dunlap FE, Ellis CN, Connolly MA, Levy SF.Comparison of the efficacy and safety of a combination topical gel formulationof benzoyl peroxide and clindamycin with benzoyl peroxide,clindamycin and vehicle gel in the treatments of acne vulgaris. Am JClin Dermatol 2001; 2: 33–39.

148 Bojar RA, Eady EA, Jones CE, Cunliffe WJ, Holland KT. Inhibition oferythromycin-resistant propionibacteria on the skin of acne patients bytopical erythromycin with and without zinc. Br J Dermatol 1994; 130:329–336.

149 Habbema L, Koopmans B, Menke HE, Doornweerd S, De Boulle K. A4% erythromycin and zinc combination (Zineryt) versus 2% erythromycin(Eryderm) in acne vulgaris: a randomized, double-blind comparativestudy. Br J Dermatol 1989; 121: 497–502.

150 Stoughton RB, Cornell RC, Gange RW, Walter JF. Double-blind comparisonof topical 1 percent clindamycin phosphate (Cleocin T) andoral tetracycline 500 mg ⁄ day in the treatment of acne vulgaris. Cutis1980; 26: 424–425, 429.

151 Rapaport M, Puhvel SM, Reisner RM. Evaluation of topical erythromycinand oral tetracycline in acne vulgaris. Cutis 1982; 30: 122–126,130, 132–125.

152 Sheehan-Dare RA, Papworth-Smith J, Cunliffe WJ. A double-blindcomparison of topical clindamycin and oral minocycline in the treatmentof acne vulgaris. Acta Derm Venereol 1990; 70: 534–537.

153 Katsambas A, Towarky AA, Stratigos J. Topical clindamycin phosphatecompared with oral tetracycline in the treatment of acne vulgaris. Br JDermatol 1987; 116: 387–391.

154 Borglund E, Hagermark O, Nord CE. Impact of topical clindamycinand systemic tetracycline on the skin and colon microflora in patientswith acne vulgaris. Scand J Infect Dis Suppl 1984; 43: 76–81.

155 Hjorth N, Graupe K. Azelaic acid for the treatment of acne. A clinicalcomparison with oral tetracycline. Acta Derm Venereol Suppl (Stockh)1989; 143: 45–48.

156 Drake LA. Comparative efficacy and tolerance of Cleocin T topical gel(clindamycin phosphate topical gel) versus oral minocycline in thetreatment of acne vulgaris. unpublished. 1980.

157 Peacock CE, Price C, Ryan BE, Mitchell AD. Topical clindamycin(Dalacin T(TM)) compared to oral minocycline (Minocin 50(TM)) intreatment of acne vulgaris. A randomized observer-blind controlledtrial in three university student health centres. Clin Trials J 1990; 27:219–228.

158 Ozolins M, Eady EA, Avery A et al. Randomised controlled multipletreatment comparison to provide a cost-effectiveness rationale for theselection of antimicrobial therapy in acne. Health Technol Assess 2005;9: iii–212.

159 Ozolins M, Eady EA, Avery AJ et al. Comparison of five antimicrobialregimens for treatment of mild to moderate inflammatory facial acnevulgaris in the community: randomised controlled trial. Lancet 2004;364: 2188–2195.

160 Bladon PT, Burke BM, Cunliffe WJ, Forster RA, Holland KT, King K.Topical azelaic acid and the treatment of acne: a clinical and laboratorycomparison with oral tetracycline. Br J Dermatol 1986; 114: 493–499.

161 Mareledwane NG. A randomized, open-label, comparative study of oraldoxycycline 100 mg vs. 5% topical benzoyl peroxide in the treatment ofmild to moderate acne vulgaris. Int J Dermatol 2006; 45: 1438–1439.

162 Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S,Kang S. Combination therapy with adapalene gel 0.1% and doxycyclinefor severe acne vulgaris: a multicenter, investigator-blind, randomized,controlled study. Skinmed 2005; 4: 138–146.

163 Cunliffe WJ, Meynadier J, Alirezai M et al. Is combined oral and topicaltherapy better than oral therapy alone in patients with moderate tomoderately severe acne vulgaris? A comparison of the efficacy andsafety of lymecyclineplus adapalene gel 0.1%, versus lymecycline plusgel vehicle. J Am Acad Dermatol 2003; 49: S218–S226.

164 Gollnick HP, Graupe K, Zaumseil RP. Comparison of combined azelaicacid cream plus oral minocycline with oral isotretinoin in severeacne. Eur J Dermatol 2001; 11: 538–544.

165 Oprica C, Emtestam L, Hagstromer L, Nord CE. Clinical and microbiologicalcomparisons of isotretinoin vs. tetracycline in acne vulgaris.Acta Derm Venereol 2007; 87: 246–254.

166 Dreno B, Moyse D, Alirezai M et al. Multicenter randomized comparativedouble-blind controlled clinical trial of the safety and efficacyof zinc gluconate versus minocycline hydrochloride in thetreatment of inflammatory acne vulgaris. Dermatology 2001; 203:135–140.

167 Cunliffe WJ, Burke B, Dodman B, Gould DJ. A double-blind trial of azinc sulphate ⁄ citrate complex and tetracycline in the treatment of acnevulgaris. Br J Dermatol 1979; 101: 321–325.

168 Carlborg L. Cyproterone acetate versus levonorgestrel combined withethinyl estradiol in the treatment of acne. Results of a multicenterstudy. Acta Obstet Gynecol Scand Suppl 1986; 134: 29–32.

169 Lachnit-Fixson U, Kaufmann J. [Therapy of androgenization symptoms:double blind study of an antiandrogen preparation (SH B 209AB) against neogynon (author’s transl)]. Med Klin 1977; 72:1922–1926.

170 Wishart JM. An open study of Triphasil and Diane 50 in the treatmentof acne. Australas J Dermatol 1991; 32: 51–54.

171 Vartiainen M, de Gezelle H, Broekmeulen CJ. Comparison of the effecton acne with a combiphasic desogestrel-containing oral contraceptiveand a preparation containing cyproterone acetate. Eur J Contracept ReprodHealth Care 2001; 6: 46–53.

172 Charoenvisal C, Thaipisuttikul Y, Pinjaroen S et al. Effects on acne oftwo oral contraceptives containing desogestrel and cyproterone acetate.Int J Fertil Menopausal Stud 1996; 41: 423–429.

173 Dieben TO, Vromans L, Theeuwes A, Bennink HJ. The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35in women with acne. Contraception 1994; 50: 373–382.

174 Erkkola R, Hirvonen E, Luikku J, Lumme R, Mannikko H, Aydinlik S.Ovulation inhibitors containing cyproterone acetate or desogestrel inthe treatment of hyperandrogenic symptoms. Acta Obstet GynecolScand 1990; 69: 61–65.

175 Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N. Acne resolutionrates: results of a single-blind, randomized, controlled, parallelphase III trial with EE ⁄ CMA (Belara) and EE ⁄ LNG (Microgynon).Dermatology 2001; 203: 38–44.

176 Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of acombined contraceptive containing drospirenone to a triphasic preparationcontaining norgestimate in acne treatment. Cutis 2004; 74:123–130.

177 Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of lifeand acne with two low-dose oral contraceptives containing 20 microgethinylestradiol. Contraception 2004; 69: 469–476.

178 Rosen MP, Breitkopf DM, Nagamani M. A randomized controlled trialof second- versus third-generation oral contraceptives in the treatmentof acne vulgaris. Am J Obstet Gynecol 2003; 188: 1158–1160.

179 Palatsi R, Hirvensalo E, Liukko P et al. Serum total and unbound testosteroneand sex hormone binding globulin (SHBG) in female acnepatients treated with two different oral contraceptives. Acta DermVenereol 1984; 64: 517–523.

180 Monk BE, Almeyda JA, Caldwell IW et al. Efficacy of low-dose cyproteroneacetate compared with minocycline in the treatment of acnevulgaris. Clin Exp Dermatol 1987; 12: 319–322.

181 Greenwood R, Brummitt L, Burke B, Cunliffe WJ. Acne: double blindclinical and laboratory trial of tetracycline, oestrogen-cyproterone acetateacetate,and combined treatment. Br Med J (Clin Res Ed) 1985; 291:1231–1235.

182 Papageorgiou P, Katsambas A, Chu A. Phototherapy with blue(415 nm) and red (660 nm) light in the treatment of acne vulgaris. BrJ Dermatol 2000; 142: 973–978.

183 Tzung TY, Wu KH, Huang ML. Blue light phototherapy in the treatmentof acne. Photodermatol Photoimmunol Photomed 2004; 20: 266–269.

184 Feucht CL, Allen BS, Chalker DK, Smith JG Jr. Topical erythromycinwith zinc in acne. A double-blind controlled study. J Am Acad Dermatol1980; 3: 483–491.

185 Stainforth J, Macdonald-Hull S, Papworth-Smith JW et al. A singleblindcomparison of topical erythromycin ⁄ zinc lotion and oral minocyclinein the treatment of acne vulgaris. J Dermatolog Treat 1993; 4:119–122.

186 Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematicreview. Clin Ther 2005; 27: 1329–1342.

187 Garner SE, Eady EA, Popescu C, Newton J, Li WA. Minocycline foracne vulgaris: efficacy and safety. Cochrane Database Syst Rev(Online).2003; 1: CD002086.

188 Dunlap FE, Mills OH, Tuley MR, Baker MD, Plott RT. Adapalene0.1% gel for the treatment of acne vulgaris: its superiority comparedto tretinoin 0.025% cream in skin tolerance and patient preference. BrJ Dermatol 1998; 139(Suppl 52): 17–22.

189 Egan N, Loesche MC, Baker MM. Randomized, controlled, bilateral(split-face) comparison trial of the tolerability and patient preferenceof adapalene gel 0.1% and tretinoin microsphere gel 0.1% for thetreatment of acne vulgaris. Cutis 2001; 68: 20–24.

190 Peck GL, Olsen TG, Butkus D et al. Isotretinoin versus placebo in thetreatment of cystic acne. A randomized double-blind study. J Am AcadDermatol 1982; 6: 735–745.

191 Strauss JS, Leyden JJ, Lucky AW et al. A randomized trial of the efficacyof a new micronized formulation versus a standard formulationof isotretinoin in patients with severe recalcitrant nodular acne. J AmAcad Dermatol 2001; 45: 187–195.

192 Strauss JS, Rapini RP, Shalita AR et al. Isotretinoin therapy for acne:results of a multicenter dose-response study. J Am Acad Dermatol1984; 10: 490–496.

193 Jones DH, King K, Miller AJ, Cunliffe WJ. A dose-response study ofI3-cis-retinoic acid in acne vulgaris. Br J Dermatol 1983; 108: 333–343.

194 King K, Jones DH, Daltrey DC, Cunliffe WJ. A double-blind study ofthe effects of 13-cis-retinoic acid on acne, sebum excretion rate andmicrobial population. Br J Dermatol 1982; 107: 583–590.

195 van der Meeren HL, van der Schroeff JG, Stijnen T, van Duren JA,van der Dries HA, van Voorst Vader PC. Dose-response relationshipin isotretinoin therapy for conglobate acne. Dermatologica 1983; 167:299–303.

196 Al Mishari MA. A study of isotretinoin (Roaccutan) in nodulocysticacne. Clin Trials J 1986; 23: 1–5.

197 Mandekou-Lefaki I, Delli F, Teknetzis A, Euthimiadou R, KarakatsanisG. Low-dose schema of isotretinoin in acne vulgaris. Int J Clin PharmacolRes 2003; 23: 41–46.

198 Plewig G, Gollnick H, Meigel W, Wokalek H. [13-cis retinoic acid inthe oral therapy of acne conglobata. Results of a multi-center study].Hautarzt 1981; 32: 634–646.

199 Pigatto PD, Finzi AF, Altomare GF, Polenghi MM, Vergani C, VigottiG. Isotretinoin versus minocycline in cystic acne: a study of lipidmetabolism. Dermatologica 1986; 172: 154–159.

200 Lester RS, Schachter GD, Light MJ. Isotretinoin and tetracycline in themanagement of severe nodulocystic acne. Int J Dermatol 1985; 24:252–257.

201 Dhir R, Gehi NP, Agarwal R, More YE. Oral isotretinoin is as effectiveas a combination of oral isotretinoin and topical anti-acne agents innodulocystic acne. Indian J Dermatol Venereol Leprol 2008; 74: 187.

202 Simonart T, Dramaix M, De Maertelaer V. Efficacy of tetracyclines inthe treatment of acne vulgaris: a review. Br J Dermatol 2008; 158: 208–216.

203 Panzer JD, Poche W, Meek TJ, Derbes VJ, Atkinson W. Acne treatment:a comparative efficacy trial of clindamycin and tetracycline.Cutis 1977; 19: 109–111.

204 Poulos ET, Tedesco FJ. Acne vulgaris: double-blind trial comparingtetracycline and clindamycin. Arch Dermatol 1976; 112: 974–976.

205 Al-Mishari MA. Clinical and bacteriological evaluation of tetracyclineand erythromycin in acne vulgaris. Clin Ther 1987; 9: 273–280.

206 Brandt H, Attila P, Ahokas T et al. Erythromycin acistrate – an alternativeoral treatment for acne. J Dermatolog Treat 1994; 5: 3–5.

207 Gammon WR, Meyer C, Lantis S, Shenefelt P, Reizner G, Cripps DJ.Comparative efficacy of oral erythromycin versus oral tetracycline inthe treatment of acne vulgaris. A double-blind study. J Am Acad Dermatol1986; 14: 183–186.

208 Association Mieux prescrire (Editeur scientifique). Moins d’effets inde´-sirables avec la doxycycline qu’avec la minocycline. Rev Prescrire 2009;29: 354.

209 Ochsendorf F. Minocycline in acne vulgaris: benefits and risks. Am JClin Dermatol 2010; 11: 327–341.

210 Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline – adose-related phenomenon. Clin Exp Dermatol 1993; 18: 425–427.

211 Lim DS, Murphy GM. High-level ultraviolet A photoprotection isneeded to prevent doxycycline phototoxicity: lessons learned in EastTimor. Br J Dermatol 2003; 149: 213–214.

212 Bjellerup M, Ljunggren B. Differences in phototoxic potency should beconsidered when tetracyclines are prescribed during summer-time. Astudy on doxycycline and lymecycline in human volunteers, using anobjective method for recording erythema. Br J Dermatol 1994; 130:356–360.

213 European Directive for systemic isotretinoin prescription. EMEA –Committee for Proprietary Medicinal Products (CPMP). [WWWdocument]. URL http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Isotretinoin_29/WC500010882.pdf (lastaccessed: 6 January 2012), 2003.

214 Ganceviciene R, Zouboulis CC. Isotretinoin: state of the art treatmentfor acne vulgaris. J Dtsch Dermatol Ges 2010; 8(Suppl 1):S47–S59.

215 Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin inacne. J Am Acad Dermatol 1992; 27: S2–S7.

216 Strauss JS, Krowchuk DP, Leyden JJ et al. Guidelines of care for acnevulgaris management. J Am Acad Dermatol 2007; 56: 651–663.

217 Cunliffe WJ, van de Kerkhof PC, Caputo R et al. Roaccutane treatmentguidelines: results of an international survey. Dermatology 1997;194: 351–357.

218 Layton AM. Optimal management of acne to prevent scarring andpsychological sequelae. Am J Clin Dermatol 2001; 2: 135–141.

219 Rubinow DR, Peck GL, Squillace KM, Gantt GG. Reduced anxiety anddepression in cystic acne patients after successful treatment with oralisotretinoin. J Am Acad Dermatol 1987; 17: 25–32.

220 Layton AM, Dreno B, Gollnick HPM, Zouboulis CC. A review of theEuropean Directive for prescribing systemic isotretinoin for acne vulgaris.J Eur Acad Dermatol Venereol 2006; 20: 773–776.

221 Marqueling AL, Zane LT. Depression and suicidal behavior in acnepatients treated with isotretinoin: a systematic review. Semin CutanMed Surg 2007; 26: 210–220.

222 Ross JI, Snelling AM, Eady EA et al. Phenotypic and genotypic characterizationof antibiotic-resistant Propionibacterium acnes isolated fromacne patients attending dermatology clinics in Europe, the U.S.A.,Japan and Australia. Br J Dermatol 2001; 144: 339–346.

223 Ross JI, Snelling AM, Carnegie E et al. Antibiotic-resistant acne: lessonsfrom Europe. Br J Dermatol 2003; 148: 467–478.

224 Eady EA, Cove JH. Topical antibiotic therapy: current status andfuture prospects. Drugs Exp Clin Res 1990; 16: 423–433.

225 Oprica C, Nord CE, Bacteria ESGoARiA. European surveillance studyon the antibiotic susceptibility of Propionibacterium acnes. Clin MicrobiolInfect 2005; 11: 204–213.

226 Nord CE, Oprica C. Antibiotic resistance in Propionibacteriumacnes. Microbiological and clinical aspects. Anaerobe 2006; 12: 207–210.

227 Eady EA. Bacterial resistance in acne. Dermatology 1998; 196: 59–66.228 Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ. Effect of antibioticson the oropharyngeal flora in patients with acne. Arch Dermatol2003; 139: 467–471.

229 Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistantpropionibacteria in antibiotic treated acne patients: association withtherapeutic failure. Br J Dermatol 1989; 121: 51–57.

230 Simonart T, Dramaix M. Treatment of acne with topical antibiotics:lessons from clinical studies. Br J Dermatol 2005; 153: 395–403.

231 Cunliffe WJ, Forster RA, Greenwood ND et al. Tetracycline and acnevulgaris: a clinical and laboratory investigation. Br Med J 1973; 4:332–335.

232 Bettoli V, Mantovani L, Borghi A. Adapalene 0.1% Cream after OralIsotretinoin: Evaluation of the Acne Recurrence Incidence. 15th AnnualEADV Congress. Rhodes. Medimond International Proceedings, Bologna,Italy, 2006.

233 Thiboutot DM, Shalita AR, Yamauchi PS et al. Adapalene gel, 0.1%, asmaintenance therapy for acne vulgaris: a randomized, controlled,investigator-blind follow-up of a recent combination study. ArchDermatol 2006; 142: 597–602.

234 Zhang JZ, Li LF, Tu YT, Zheng J. A successful maintenance approachin inflammatory acne with adapalene gel 0.1% after an initial treatmentin combination with clindamycin topical solution 1% or aftermonotherapy with clindamycin topical solution 1%. J DermatologTreat 2004; 15: 372–378.

235 Alirezai M, George SA, Coutts I et al. Daily treatment with adapalenegel 0.1% maintains initial improvement of acne vulgaris previouslytreated with oral lymecycline. Eur J Dermatol 2007; 17: 45–51.

236 Graupe K, Cunliffe WJ, Gollnick HP, Zaumseil RP. Efficacy and safetyof topical azelaic acid (20 percent cream): an overview of results fromEuropean clinical trials and experimental reports. Cutis 1996; 57: 20–35.

237 Goltz RW, Coryell GM, Schnieders JR, Neidert GL. A comparison ofCleocin T 1 percent solution and Cleocin T 1 percent lotion in thetreatment of acne vulgaris. Cutis 1985; 36: 265–268.

238 Parker F. A comparison of clindamycin 1% solution versus clindamycin1% gel in the treatment of acne vulgaris. Int J Dermatol 1987; 26:121–122.

239 Leyden JJ, Shalita AR, Saatjian GD, Sefton J. Erythromycin 2% gel incomparison with clindamycin phosphate 1% solution in acne vulgaris.J Am Acad Dermatol 1987; 16: 822–827.

240 Mills OH, Berger RS, Kligman AM, McElroy JA, Di Matteo J. A comparativestudy of Erycette(TM) vs Cleocin-T(TM). Adv Ther 1992; 9:14–20.

241 Thomas DR, Raimer S, Smith EB. Comparison of topical erythromycin1.5 percent solution versus topical clindamycin phosphate 1.0 percentsolution in the treatment of acne vulgaris. Cutis 1982; 29: 624–625,628–632.

242 Shahlita AR, Smith EB, Bauer E. Topical erythromycin v clindamycintherapy for acne. A multicenter, double-blind comparison. Arch Dermatol1984; 120: 351–355.

243 Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluationof nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream.Eur J Dermatol 2006; 16: 48–55.

244 Patel VB, Misra AN, Marfatia YS. Preparation and comparative clinicalevaluation of liposomal gel of benzoyl peroxide for acne. Drug Dev IndPharm 2001; 27: 863–869.

245 Cunliffe WJ, Holland KT. The effect of benzoyl peroxide on acne. ActaDerm Venereol 1981; 61: 267–269.

246 Fyrand O, Jakobsen HB. Water-based versus alcohol-based benzoylperoxide preparations in the treatment of acne vulgaris. Dermatologica1986; 172: 263–267.

247 Patel VB, Misra A, Marfatia YS. Topical liposomal gel of tretinoin forthe treatment of acne: research and clinical implications. Pharm DevTechnol 2000; 5: 455–464.

248 Schafer-Korting M, Korting HC, Ponce-Poschl E. Liposomal tretinoinfor uncomplicated acne vulgaris. Clin Investig 1994; 72: 1086–1091.

249 Berger R, Rizer R, Barba A et al. Tretinoin gel microspheres 0.04%versus 0.1% in adolescents and adults with mild to moderate acne vulgaris:a 12-week, multicenter, randomized, double-blind, parallelgroup,phase IV trial. Clin Ther 2007; 29: 1086–1097.

250 Thiboutot D, Jarratt M, Rich P, Rist T, Rodriguez D, Levy S. A randomized,parallel, vehicle-controlled comparison of two erythromycin⁄ benzoyl peroxide preparations for acne vulgaris. Clin Ther 2002;24: 773–785.

251 Schachner L, Eaglstein W, Kittles C, Mertz P. Topical erythromycinand zinc therapy for acne. J Am Acad Dermatol 1990; 22:253–260.

252 Dhawan SS. Comparison of 2 clindamycin 1%-benzoyl peroxide 5%topical gels used once daily in the management of acne vulgaris. Cutis2009; 83: 265–272.

253 Kircik L. Community-based trial results of combination clindamycin1%–benzoyl peroxide 5% topical gel plus tretinoin microsphere gel0.04% or 0.1% or adapalene gel 0.1% in the treatment of moderate tosevere acne. Cutis 2007; 80: 10–14.

254 Kircik LH. Comparative efficacy and safety results of two topical combinationacne regimens. J Drugs Dermatol 2009; 8: 624–630.

255 Cunliffe WJ, Fernandez C, Bojar R, Kanis R, West F. An observerblindparallel-group, randomized, multicentre clinical and microbiologicalstudy of a topical clindamycin ⁄ zinc gel and a topical clindamycinlotion in patients with mild ⁄ moderate acne. J Dermatolog Treat2005; 16: 213–218.

256 Del Rosso J. Study results of benzoyl peroxide 5% ⁄ clindamycin. JDrugs Dermatol 2007; 6: 616–622.

257 Shalita AR, Rafal ES, Anderson DN, Yavel R, Landow S, Lee WL.Compared efficacy and safety of tretinoin 0.1% microsphere gel aloneand in combination with benzoyl peroxide 6% cleanser for the treatmentof acne vulgaris. Cutis 2003; 72: 167–172.

258 Wolf JE Jr, Kaplan D, Kraus SJ et al. Efficacy and tolerability of combinedtopical treatment of acne vulgaris with adapalene and clindamycin:a multicenter, randomized, investigator-blinded study. J Am AcadDermatol 2003; 49: S211–S217.

259 NilFroushzadeh MA, Siadat AH, Baradaran EH, Moradi S. Clindamycinlotion alone versus combination lotion of clindamycin phosphateplus tretinoin versus combination lotion of clindamycin phosphateplus salicylic acid in the topical treatment of mild to moderate acnevulgaris: a randomized control trial. Indian J Dermatol Venereol Leprol2009; 75: 279–282.

260 Cambazard F. Clinical efficacy of Velac, a new tretinoin and clindamycinphosphate gel in acne vulgaris. J Eur Acad Dermatol Venereol 1998;11(Suppl 1): S20–S27; discussion S28-29.

261 Zouboulis CC, Derumeaux L, Decroix J, Maciejewska-Udziela B,Cambazard F, Stuhlert A. A multicentre, single-blind, randomizedcomparison of a fixed clindamycin phosphate ⁄ tretinoin gel formulation(Velac) applied once daily and a clindamycin lotion formulation(Dalacin T) applied twice daily in the topical treatment of acne vulgaris.Br J Dermatol 2000; 143: 498–505.

262 Richter JR, Forstrom LR, Kiistala UO, Jung EG. Efficacy of the fixed1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac)and a proprietary 0.025% tretinoin gel formulation (Aberela) in thetopical control of facial acne. J Eur Acad Dermatol Venereol 1998; 11:227–233.

263 Ko HC, Song M, Seo SH, Oh CK, Kwon KS, Kim MB. Prospective,open-label, comparative study of clindamycin 1% ⁄ benzoyl peroxide5% gel with adapalene 0.1% gel in Asian acne patients: efficacy andtolerability. J Eur Acad Dermatol Venereol 2009; 23: 245–250.

264 Langner A, Chu A, Goulden V, Ambroziak M. A randomized, singleblindcomparison of topical clindamycin + benzoyl peroxide andadapalene in the treatment of mild to moderate facial acne vulgaris. BrJ Dermatol 2008; 158: 122–129.

265 Gupta AK, Lynde CW, Kunynetz RA, Amin S, Choi K, GoldsteinE. A randomized, double-blind, multicenter, parallel group study tocompare relative efficacies of the topical gels 3% erythromycin ⁄ 5%benzoyl peroxide and 0.025% tretinoin ⁄ erythromycin 4% in thetreatment of moderate acne vulgaris of the face. J Cutan Med Surg2003; 7: 31–37.

266 Marazzi P, Boorman GC, Donald AE, Davies HD. Clinical evaluationof double strength isotrexin versus benzamycin in the topical treatmentof mild to moderate acne vulgaris. J Dermatolog Treat 2002; 13:111–117.

267 Chu A, Huber FJ, Plott RT. The comparative efficacy of benzoyl peroxide5% ⁄ erythromycin 3% gel and erythromycin 4% ⁄ zinc 1.2%solution in the treatment of acne vulgaris. Br J Dermatol 1997; 136:235–238.

268 Packman AM, Brown RH, Dunlap FE, Kraus SJ, Webster GF. Treatmentof acne vulgaris: combination of 3% erythromycin and 5% benzoylperoxide in a gel compared to clindamycin phosphate lotion. Int JDermatol 1996; 35: 209–211.

269 Schachner L, Pestana A, Kittles C. A clinical trial comparing thesafety and efficacy of a topical erythromycin-zinc formulation with atopical clindamycin formulation. J Am Acad Dermatol 1990; 22: 489–495.

270 Bowman S, Gold M, Nasir A, Vamvakias G. Comparison of clindamycin⁄ benzoyl peroxide, tretinoin plus clindamycin, and the combinationof clindamycin ⁄ benzoyl peroxide and tretinoin plus clindamycin inthe treatment of acne vulgaris: a randomized, blinded study. J DrugsDermatol 2005; 4: 611–618.

271 Langner A, Sheehan-Dare R, Layton A. A randomized, single-blindcomparison of topical clindamycin + benzoyl peroxide (Duac) anderythromycin + zinc acetate (Zineryt) in the treatment of mild tomoderate facial acne vulgaris. J Eur Acad Dermatol Venereol 2007; 21:311–319.

272 Christian GL, Krueger GG. Clindamycin vs placebo as adjunctive therapyin moderately severe acne. Arch Dermatol 1975; 111: 997–1000.

273 Plewig G, Petrozzi JW, Berendes U. Double-blind study of doxycyclinein acne vulgaris. Arch Dermatol 1970; 101: 435–438.

274 Fleischer AB Jr, Dinehart S, Stough D, Plott RT. Safety and efficacy ofa new extended-release formulation of minocycline. Cutis 2006; 78:21–31.

275 Olafsson JH, Gudgeirsson J, Eggertsdottir GE, Kristjansson F. Doxycyclineversus minocycline in the treatment of acne vulgaris: a doubleblindstudy. J Dermatolog Treat 1989; 1: 15–17.

276 Cunliffe WJ, Grosshans E, Belaich S, Meynadier J, Alirezai M, ThomasL. A comparison of the efficacy and safety of lymecycline and minocyclinein patients with moderately severe acne vulgaris. Eur J Dermatol1998; 8: 161–166.

277 Bossuyt L, Bosschaert J, Richert B et al. Lymecycline in the treatmentof acne: an efficacious, safe and cost-effective alternative to minocycline.Eur J Dermatol 2003; 13: 130–135.

278 Cullen SI, Cohan RH. Minocycline therapy in acne vulgaris. Cutis1976; 17: 1208–1210, 1214.

279 Ruping KW, Tronnier H. Acne therapy: Results of a multicentre studywith minocyline. R Soc Med Serv Int Cong Symp Ser 1985; 95:109–119.

280 Dreno B, Amblard P, Agache P, Sirot S, Litoux P. Low doses of zinc gluconatefor inflammatory acne. Acta Derm Venereol 1989; 69: 541–543.

281 Orris L, Shalita AR, Sibulkin D, London SJ, Gans EH. Oral zinc therapyof acne. Absorption and clinical effect. Arch Dermatol 1978; 114:1018–1020.

282 Weimar VM, Puhl SC, Smith WH, tenBroeke JE. Zinc sulfate in acnevulgaris. Arch Dermatol 1978; 114: 1776–1778.

283 Vena GA. Comparison of two different dosing regimens with lymecycline,in association with adapalene, in inflammatory acne. Eur J Inflamm2005; 3: 89–95.

284 Leyden J, Shalita A, Hordinsky M, Swinyer L, Stanczyk FZ, WeberME. Efficacy of a low-dose oral contraceptive containing 20 microg ofethinyl estradiol and 100 microg of levonorgestrel for the treatment ofmoderate acne: a randomized, placebo-controlled trial. J Am AcadDermatol 2002; 47: 399–409.

285 Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, HarrisonDD. A randomized, controlled trial of a low-dose contraceptive containing20 microg of ethinyl estradiol and 100 microg of levonorgestrelfor acne treatment. Fertil Steril 2001; 76: 461–468.

286 Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M,Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treatingmoderate acne vulgaris. J Am Acad Dermatol 1997; 37: 746–754.

287 Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, JorizzoJL. Norgestimate and ethinyl estradiol in the treatment of acnevulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997;89: 615–622.

288 Plewig G, Cunliffe WJ, Binder N, Hoschen K. Efficacy of an oral contraceptivecontaining EE 0.03 mg and CMA 2 mg (Belara) in moderateacne resolution: a randomized, double-blind, placebo-controlled PhaseIII trial. Contraception 2009; 80: 25–33.

289 Koltun W, Lucky AW, Thiboutot D et al. Efficacy and safety of 3 mgdrospirenone ⁄ 20 mcg ethinylestradiol oral contraceptive administeredin 24 ⁄ 4 regimen in the treatment of acne vulgaris: a randomized,double-blind, placebo-controlled trial. Contraception 2008; 77: 249–256.

290 Maloney JM, Dietze P Jr, Watson D et al. Treatment of acne using a3-milligram drospirenone ⁄ 20-microgram ethinyl estradiol oral contraceptiveadministered in a 24 ⁄ 4 regimen: a randomized controlled trial.Obstet Gynecol 2008; 112: 773–781.

291 Fugere P, Percival-Smith RK, Lussier-Cacan S, Davignon J, FarquharD. Cyproterone acetate ⁄ ethinyl estradiol in the treatment of acne. Acomparative dose-response study of the estrogen component. Contraception1990; 42: 225–234.

292 Halbe HW, de Melo NR, Bahamondes L et al. Efficacy and acceptabilityof two monophasic oral contraceptives containing ethinylestradioland either desogestrel or gestodene. Eur J Contracept Reprod HealthCare 1998; 3: 113–120.

293 Koetsawang S, Charoenvisal C, Banharnsupawat L, Singhakovin S,Kaewsuk O, Punnahitanont S. Multicenter trial of two monophasicoral contraceptives containing 30 mcg ethinylestradiol and eitherdesogestrel or gestodene in Thai women. Contraception 1995; 51:225–229.

294 Mango D, Ricci S, Manna P, Miggiano GA, Serra GB. Clinical andhormonal effects of ethinylestradiol combined with gestodene and desogestrelin young women with acne vulgaris. Contraception 1996; 53:163–170.

295 Graupe K, Zaumseil RP. Skinoren – a new local therapeutic agent forthe treatment of acne vulgaris. In Macher E, Kolde G, Bro¨cker EB, eds.Jahrbuch der Dermatologie. Biermann, Zu¨lpich, 1991: 159–169.

296 Stoughton RB, Resh W. Topical clindamycin in the control of acnevulgaris. Cutis 1976; 17: 551–554.

297 Padilla RS, McCabe JM, Becker LE. Topical tetracycline hydrochloridevs. topical clindamycin phosphate in the treatment of acne: a comparativestudy. Int J Dermatol 1981; 20: 445–448.

298 Robledo AA, Lopez BE, del Pino GJ et al. Multicentric comparativestudy of the efficacy and tolerance of clindamycin phosphate 1% topicalsolution and tetracycline topical solution for the treatment of acnevulgaris. Curr Ther Res Clin Exp 1988; 43: 21–26.

299 Yong CC. Benzoyl peroxide gel therapy in acne in Singapore. Int JDermatol 1979; 18: 485–488.

300 Strauss JS, Stranieri AM. Acne treatment with topical erythromycinand zinc: effect of Propionibacterium acnes and free fatty acid composition.J Am Acad Dermatol 1984; 11: 86–89.

301 Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. J Am Acad Dermatol2006; 54: 647–651.

302 Skidmore R, Kovach R, Walker C et al. Effects of subantimicrobialdosedoxycycline in the treatment of moderate acne. Arch Dermatol2003; 139: 459–464.

303 Dubertret L, Alirezai M, Rostain G et al. The use of lymecycline in thetreatment of moderate to severe acne vulgaris: a comparison of theefficacy and safety of two dosing regimens. Eur J Dermatol 2003; 13:44–48.

304 Stewart DM, Torok HM, Weiss JS, Plott RT. Dose-ranging efficacy ofnew once-daily extended-release minocycline for acne vulgaris. Cutis2006; 78: 11–20.

305 Hersle K, Gisslen H. Minocycline in acne vulgaris: a double-blindstudy. Curr Ther Res Clin Exp 1976; 19: 339–342.

306 Lane P, Williamson DM. Treatment of acne vulgaris with tetracyclinehydrochloride: a double-blind trial with 51 patients. Br Med J 1969; 2:76–79.

307 Stewart WD, Maddin S, Nelson AJ, Danto JL. Therapeutic agents inacne vulgaris. I. Tetracycline. Can Med Assoc J 1963; 89: 1096–1097.

308 Wong RC, Kang S, Heezen JL, Voorhees JJ, Ellis CN. Oral ibuprofenand tetracycline for the treatment of acne vulgaris. J Am Acad Dermatol1984; 11: 1076–1081.

309 Toossi P, Farshchian M, Malekzad F, Mohtasham N, Kimyai-Asadi A.Subantimicrobial-dose doxycycline in the treatment of moderate facialacne. J Drugs Dermatol 2008; 7: 1149–1152.

310 Bleeker J, Hellgren L, Vincent J. Effect of systemic erythromycin stearateon the inflammatory lesions and skin surface fatty acids in acnevulgaris. Dermatologica 1981; 162: 342–349.

311 Bleeker J. Tolerance and efficacy of erythromycin stearate tablets versusenteric-coated erythromycin base capsules in the treatment of patientswith acne vulgaris. J Int Med Res 1983; 11: 38–41.

312 Pierard-Franchimont C, Goffin V, Arrese JE et al. Lymecycline and minocyclinein inflammatory acne: a randomized, double-blind intent-totreatstudy on clinical and in vivo antibacterial efficacy. Skin PharmacolAppl Skin Physiol 2002; 15: 112–119.

313 Hubbell CG, Hobbs ER, Rist T, White JW Jr. Efficacy of minocyclinecompared with tetracycline in treatment of acne vulgaris. Arch Dermatol1982; 118: 989–992.

314 Khanna N. Treatment of acne vulgaris with oral tetracyclines. Indian JDermatol Venereol Leprol 1993; 29: 74–76.

315 Samuelson JS. An accurate photographic method for grading acne: initialuse in a double-blind clinical comparison of minocycline and tetracycline.J Am Acad Dermatol 1985; 12: 461–467.

316 Akman A, Durusoy C, Senturk M, Koc CK, Soyturk D, Alpsoy E.Treatment of acne with intermittent and conventional isotretinoin: arandomized, controlled multicenter study. Arch Dermatol Res 2007;299: 467–473.

317 Kapadia N. Comparative efficacy and safety and efficacy of systemic13-cis retinoic acid 20 mg ⁄ day vs 40 mg ⁄ day in acne vulgaris. J PakAssoc Dermatolog 2005; 15: 238–241.

318 Hillstrom L, Pettersson L, Hellbe L, Kjellin A, Leczinsky CG, NordwallC. Comparison of oral treatment with zinc sulphate and placebo inacne vulgaris. Br J Dermatol 1977; 97: 681–684.

319 Go¨ransson K, Liden S, Odsell L. Oral zinc in acne vulgaris: a clinicaland methodological study. Acta Derm Venereol 1978; 58: 443–448.

320 Liden S, Goransson K, Odsell L. Clinical evaluation in acne. Acta DermVenereol Suppl (Stockh) 1980; Suppl. 89: 47–52.

321 Verma KC, Saini AS, Dhamija SK. Oral zinc sulphate therapy in acnevulgaris: a double-blind trial. Acta Derm Venereol 1980; 60: 337–340.

322 Weismann K, Wadskov S, Sondergaard J. Oral zinc sulphate therapyfor acne vulgaris. Acta Derm Venereol 1977; 57: 357–360.

323 Harrison PV. A comparison of doxycycline and minocycline in thetreatment of acne vulgaris. Clin Exp Dermatol 1988; 13: 242–244.

324 Burton J. A placebo-controlled study to evaluate the efficacy of topicaltetracycline and oral tetracycline in the treatment of mild to moderateacne. Dermatology Research Group. J Int Med Res 1990; 18: 94–103.

325 Palombo-Kinne E, Schellschmidt I, Schumacher U, Graser T. Efficacyof a combined oral contraceptive containing 0.030 mg ethinylestradiol⁄ 2 mg dienogest for the treatment of papulopustular acne in comparisonwith placebo and 0.035 mg ethinylestradiol ⁄ 2 mg cyproteroneacetate. Contraception 2009; 79: 282–289.

326 Gruber DM, Sator MO, Joura EA, Kokoschka EM, Heinze G, HuberJC. Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial. Arch Dermatol 1998; 134: 459–463.

327 Katz HI, Kempers S, Akin MD, Dunlap F, Whiting D, Norbart TC.Effect of a desogestrel-containing oral contraceptive on the skin. Eur JContracept Reprod Health Care 2000; 5: 248–255.

328 Kranzlin HT, Nap MA. The effect of a phasic oral contraceptive containingDesogestrel on seborrhea and acne. Eur J Contracept ReprodHealth Care 2006; 11: 6–13.

329 Colver GB, Mortimer PS, Dawber RP. Cyproterone acetate and twodoses of oestrogen in female acne; a double-blind comparison. Br JDermatol 1988; 118: 95–99.

330 Miller JA, Wojnarowska FT, Dowd PM et al. Anti-androgen treatmentin women with acne: a controlled trial. Br J Dermatol 1986; 114: 705–716.

331 Hongcharu W, Taylor CR, Chang Y, Aghassi D, Suthamjariya K,Anderson RR. Topical ALA-photodynamic therapy for the treatmentof acne vulgaris. J Invest Dermatol 2000; 115: 183–192.

332 Horfelt C, Stenquist B, Halldin CB, Ericson MB, Wennberg AM. Singlelow-dose red light is as efficacious as methyl-aminolevulinate – photodynamictherapy for treatment of acne: clinical assessment and fluorescencemonitoring. Acta Derm Venereol 2009; 89: 372–378.

333 Horfelt C, Funk J, Frohm-Nilsson M, Wiegleb Edstrom D, WennbergAM. Topical methyl aminolaevulinate photodynamic therapy for treatmentof facial acne vulgaris: results of a randomized, controlled study.Br J Dermatol 2006; 155: 608–613.

334 Na JI, Suh DH. Red light phototherapy alone is effective for acne vulgaris:randomized, single-blinded clinical trial. Dermatol Surg 2007; 33:1228–1233; discussion 1233.

335 Pollock B, Turner D, Stringer MR et al. Topical aminolaevulinic acidphotodynamictherapy for the treatment of acne vulgaris: a study ofclinical efficacy and mechanism of action. Br J Dermatol 2004; 151:616–622.

336 Gold MH, Rao J, Goldman MP et al. A multicenter clinical evaluationof the treatment of mild to moderate inflammatory acne vulgaris ofthe face with visible blue light in comparison to topical 1% clindamycinantibiotic solution. J Drugs Dermatol 2005; 4: 64–70.

337 Sami NA, Attia AT, Badawi AM. Phototherapy in the treatment ofacne vulgaris. J Drugs Dermatol 2008; 7: 627–632.

338 Haedersdal M, Togsverd-Bo K, Wiegell SR, Wulf HC. Long-pulsed dyelaser versus long-pulsed dye laser-assisted photodynamic therapy foracne vulgaris: a randomized controlled trial. J Am Acad Dermatol2008; 58: 387–394.

339 Jung JY, Choi YS, Yoon MY, Min SU, Suh DH. Comparison of apulsed dye laser and a combined 585 ⁄ 1,064-nm laser in the treatmentof acne vulgaris. Dermatol Surg 2009; 35: 1181–1187.

340 Leheta TM. Role of the 585-nm pulsed dye laser in the treatment ofacne in comparison with other topical therapeutic modalities. J CosmetLaser Ther 2009; 11: 118–124.

341 Orringer JS, Kang S, Hamilton T et al. Treatment of acne vulgaris witha pulsed dye laser: a randomized controlled trial. JAMA 2004; 291:2834–2839.

342 Seaton ED, Charakida A, Mouser PE, Grace I, Clement RM, Chu AC.Pulsed-dye laser treatment for inflammatory acne vulgaris: randomisedcontrolled trial. Lancet 2003; 362: 1347–1352.

343 Bowes LE, Manstein D, Rox Andersen R. Effects of 532 nm KTP laserexposure on acne and sebaceous glands. Lasers Med Sci 2003; 18: S6–S7.

344 Baugh WP, Kucaba WD. Nonablative phototherapy for acne vulgarisusing the KTP 532 nm laser. Dermatol Surg 2005; 31: 1290–1296.

345 Oh SH, Ryu DJ, Han EC, Lee KH, Lee JH. A comparative study oftopical 5-aminolevulinic acid incubation times in photodynamic therapywith intense pulsed light for the treatment of inflammatory acne.Dermatol Surg 2009; 35: 1918–1926.

346 Rojanamatin J, Choawawanich P. Treatment of inflammatory facialacne vulgaris with intense pulsed light and short contact of topical 5-aminolevulinic acid: a pilot study. Dermatol Surg 2006; 32: 991–996;discussion 996–997.

347 Santos MA, Belo VG, Santos G. Effectiveness of photodynamic therapywith topical 5-aminolevulinic acid and intense pulsed light versusintense pulsed light alone in the treatment of acne vulgaris: comparativestudy. Dermatol Surg 2005; 31: 910–915.

348 Paithankar DY, Ross EV, Saleh BA, Blair MA, Graham BS. Acne treatmentwith a 1,450 nm wavelength laser and cryogen spray cooling.Lasers Surg Med 2002; 31: 106–114.

349 Uebelhoer NS, Bogle MA, Dover JS, Arndt KA, Rohrer TE. Comparisonof stacked pulses versus double-pass treatments of facial acne witha 1,450-nm laser. Dermatol Surg 2007; 33: 552–559.

350 Wang SQ, Counters JT, Flor ME, Zelickson BD. Treatment of inflammatoryfacial acne with the 1,450 nm diode laser alone versus microdermabrasionplus the 1,450 nm laser: a randomized, split-face trial.Dermatol Surg 2006; 32: 249–255; discussion 255.

351 Orringer JS, Kang S, Maier L et al. A randomized, controlled, split-faceclinical trial of 1320-nm Nd:YAG laser therapy in the treatment ofacne vulgaris. J Am Acad Dermatol 2007; 56: 432–438.

352 Orringer JS, Sachs DL, Bailey E, Kang S, Hamilton T, Voorhees JJ.Photodynamic therapy for acne vulgaris: a randomized, controlled,split-face clinical trial of topical aminolevulinic acid and pulsed dyelaser therapy. J Cosmet Dermatol 2010; 9: 28–34.

353 Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris usingmethyl aminolaevulinate: a blinded, randomized, controlled trial. Br JDermatol 2006; 154: 969–976.

354 Horfelt C, Stenquist B, Larko O, Faergemann J, Wennberg AM.Photodynamic therapy for acne vulgaris: a pilot study of the doseresponseand mechanism of action. Acta Derm Venereol 2007; 87: 325–329.

355 Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M,Weber ME. Effect of low-dose oral contraceptives on androgenicmarkers and acne. Contraception 1999; 60: 255–262.

356 Gerlinger C, Sta¨dtler G, Go¨tzelmann R, Graupe K, Endrikat J. A noninferioritymargin for acne lesion counts. Drug Information J 2008;42: 607–615.

Evidence-Based Recommendations for the Diagnosis and Treatment of Pediatric Acne. American Academy of Pediatrics. 2013

1. Eichenfield LF, Fowler JF Jr, Fried RG, Friedlander SF, Levy ML, Webster GF. Perspectives on therapeutic options for acne: an update. Semin Cutan Med Surg. 2010; 29(2 suppl 1):13–16
2. Tom WL, Friedlander SF. Acne through the ages: case-based observations through childhood and adolescence. Clin Pediatr (Phila). 2008;47(7):639–651
3. Krakowski AC, Eichenfield LF. Pediatric acne: clinical presentations, evaluation, and management. J Drugs Dermatol.

2007;6(6):589–593

4. Cantatore-Francis JL, Glick SA. Childhood acne: evaluation and management. Dermatol Ther. 2006;19(4):202–209
5. Jansen T, Burgdorf WH, Plewig G. Pathogenesis and treatment of acne in childhood. Pediatr Dermatol. 1997;14(1):17–21
6. Piggott CDS, Eichenfield LF, Lucky AW. Acne in children. In: Shalita AR, Del Rosso JQ, Webster GF, eds. Acne Vulgaris. New York, NY: Informa Healthcare; 2011:182–197
7. Marcoux D, McCuaig CC, Powell J. Prepubertal acne: clinical presentation, evaluation, and treatment. J Cutan Med Surg. 1998;2(suppl 3):2–6
8. Cunliffe WJ, Baron SE, Coulson IH. A clinical and therapeutic study of 29 patients with infantile acne. Br J Dermatol. 2001; 145(3):463–466
9. Herane MI, Ando I. Acne in infancy and acne genetics. Dermatology. 2003;206(1):24–28
10. Lucky AW, Koltun W, Thiboutot D, et al. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinylestradiol in the treatment of acne vulgaris: a randomized, double-blind, placebocontrolled study evaluating lesion counts and participant self-assessment. Cutis. 2008;82(2):143–150
11. Gollnick H, Cunliffe W, Berson D, et al; Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):S1–S37
12. Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol. 2007;21(6):747–753
13. Demircay Z, Seckin D, Senol A, Demir F. Patient’s perspective: an important issue not to be overlooked in assessing acne severity. Eur J Dermatol. 2008;18(2):181–184
14. Aktan S, Ozmen E, Sanli B. Anxiety, depression, and nature of acne vulgaris in adolescents. Int J Dermatol. 2000;39(5):354–357
15. Kellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol. 1999;140(2):273–282
16. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life

in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999;140(4):672–676

17. Tan JK, Vasey K, Fung KY. Beliefs and perceptions of patients with acne. J Am Acad Dermatol. 2001;44(3):439–445

Guidelines of care for acne vulgaris management. American Academy of Dermatology. 2007

1. Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman JL, Ewigman B, et al. Simplifying the language of evidence to improve patient care: Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in medical literature. J Fam Pract 2004;53:111-20.
2. Lehmann HP, Robinson KA, Andrews JS, Holloway V, Goodman SN. Acne therapy: a methodologic review. J Am Acad Dermatol 2002;47:231-40.
3. Pochi PE, Shalita AR, Strauss JS, Webster SB, Cunliffe WJ, Katz HI, et al. Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24 and 25, 1990. J Am Acad Dermatol 1991;24:495-500.
4. Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol 1997;36:416-8.
5. Allen BS, Smith JG Jr. Various parameters for grading acne vulgaris. Arch Dermatol 1982;118:23-5.
6. Lucky AW, Barber BL, Girman CJ, Williams J, Ratterman J, Waldstreicher J. A multirater validation study to assess the reliability of acne lesion counting. J Am Acad Dermatol 1996;35:559-65.
7. Cook CH, Centner RL, Michaels SE. An acne grading method using photographic standards. Arch Dermatol 1979;115:571-5.
8. Gibson JR, Harvey SG, Barth J, Darley CR, Reshad H, Burke CA. Assessing inflammatory acne vulgaris—correlation between clinical and photographic methods. Br J Dermatol 1984; 111(suppl 27):168-70.
9. Burke BM, Cunliffe WJ. The assessment of acne vulgaris—the Leeds technique. Br J Dermatol 1984;111:83-92.
10. Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol 1992;17: 1-3.
11. Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995;132:942-9.
12. Martin AR, Lookingbill DP, Botek A, Light J, Thiboutot D, Girman CJ. Health-related quality of life among patients with facial acne—assessment of a new acne-specific questionnaire. Clin Exp Dermatol 2001;26:380-5.
13. Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998;134:454-8.
14. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999;140:672-6.
15. Gupta MA, Johnson AM, Gupta AK. The development of an Acne Quality of Life scale: reliability, validity, and relation to subjective acne severity in mild to moderate acne vulgaris. Acta Derm Venereol 1998;78:451-6.
16. Cove JH, Cunliffe WJ, Holland KT. Acne vulgaris: is the bacterial population size significant? Br J Dermatol 1980; 102:277-80.
17. Bojar RA, Hittel N, Cunliffe WJ, Holland KT. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Drugs 1995;49(suppl 2):164-7.
18. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989;121: 51-7.
19. Harkaway KS, McGinley KJ, Foglia AN, Lee WL, Fried F, Shalita AR, et al. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol 1992;126:586-90.
20. Lawrence DM, Katz M, Robinson TW, Newman MC, McGarrigle HH, Shaw M, et al. Reduced sex hormone binding globulin and derived free testosterone levels in women with severe acne. Clin Endocrinol (Oxf) 1981;15:87-91.
21. Bunker CB, Newton JA, Kilborn J, Patel A, Conway GS, Jacobs HS, et al. Most women with acne have polycystic ovaries. Br J Dermatol 1989;121:675-80.
22. Lucky AW, Biro FM, Simbartl LA, Morrison JA, Sorg NW. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. J Pediatr 1997; 130:30-9.
23. Timpatanapong P, Rojanasakul A. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. J Dermatol 1997;24:223-9.
24. Lucky AW. Endocrine aspects of acne. Pediatr Clin North Am 1983;30:495-9.
25. Christiansen JV, Gadborg E, Ludvigsen K, Meier CH, Norholm A, Pedersen D, et al. Topical tretinoin, vitamin A acid (Airol) in acne vulgaris. A controlled clinical trial. Dermatologica 1974; 148:82-9.
26. Bradford LG, Montes LF. Topical application of vitamin A acid in acne vulgaris. South Med J 1974;67:683-7.
27. Krishnan G. Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris. Practitioner 1976;216:106-9.
28. Chalker DK, Lesher JL Jr, Smith JG Jr, Klauda HC, Pochi PE, Jacoby WS, et al. Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, doubleblind investigation. J Am Acad Dermatol 1987;17:251-4.
29. Shalita A, Weiss JS, Chalker DK, Ellis CN, Greenspan A, Katz HI, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol 1996;34: 482-5.
30. Clucas A, Verschoore M, Sorba V, Poncet M, Baker M, Czernielewski J. Adapalene 0.1% gel is better tolerated than tretinoin 0.025% gel in acne patients. J Am Acad Dermatol 1997;36:S116-8.
31. Cunliffe WJ, Caputo R, Dreno B, Forstrom L, Heenen M, Orfanos CE, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol 1997;36:S126-34.
32. Dunlap FE, Mills OH, Tuley MR, Baker MD, Plott RT. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol 1998;139(suppl 52):17-22.
33. Galvin SA, Gilbert R, Baker M, Guibal F, Tuley MR. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol 1998;139(suppl 52):34-40.
34. Grosshans E, Marks R, Mascaro JM, Torras H, Meynadier J, Alirezai M, et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol 1998;139(suppl 52):26-33.
35. Mills OH Jr, Berger RS. Irritation potential of a new topical tretinoin formulation and a commercially-available tretinoin formulation as measured by patch testing in human subjects. J Am Acad Dermatol 1998;38:S11-6.
36. Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J Dermatol 2002;147:523-7.
37. Kakita L. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris. J Am Acad Dermatol 2000;43:S51-4.
38. Shalita AR, Chalker DK, Griffith RF, Herbert AA, Hickman JG, Maloney JM, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis 1999;63:349-54.
39. Ellis CN, Millikan LE, Smith EB, Chalker DM, Swinyer LJ, Katz IH, et al. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris. Br J Dermatol 1998;139(suppl 52):41-7.
40. Webster GF, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis 2001; 67(Suppl 6):4-9.
41. Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol 1998;38:S17-23.
42. Belknap BS. Treatment of acne with 5% benzoyl peroxide gel or 0.05% retinoic acid cream. Cutis 1979;23:856-9.
43. Bucknall JH, Murdoch PN. Comparison of tretinoin solution and benzoyl peroxide lotion in the treatment of acne vulgaris. Curr Med Res Opin 1977;5:266-8.
44. Montes LF. Acne vulgaris: treatment with topical benzoyl peroxide acetone gel. Cutis 1977;19:681-5.
45. Hughes BR, Norris JF, Cunliffe WJ. A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clin Exp Dermatol 1992;17: 165-8.
46. Cunliffe WJ, Dodman B, Ead R. Benzoyl peroxide in acne. Practitioner 1978;220:479-82.
47. Fyrand O, Jakobsen HB. Water-based versus alcohol-based benzoyl peroxide preparations in the treatment of acne vulgaris. Dermatologica 1986;172:263-7.
48. Schutte H, Cunliffe WJ, Forster RA. The short-term effects of benzoyl peroxide lotion on the resolution of inflamed acne lesions. Br J Dermatol 1982;106:91-4.
49. Yong CC. Benzoyl peroxide gel therapy in acne in Singapore. Int J Dermatol 1979;18:485-8.
50. Smith EB, Padilla RS, McCabe JM, Becker LE. Benzoyl peroxide lotion (20 percent) in acne. Cutis 1980;25:90-2.
51. Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol 1986;25:664-7.
52. Bernstein JE, Shalita AR. Topically applied erythromycin in inflammatory acne vulgaris. J Am Acad Dermatol 1980;2: 318-21.
53. Jones EL, Crumley AF. Topical erythromycin vs blank vehicle in a multiclinic acne study. Arch Dermatol 1981;117:551-3.
54. Prince RA, Busch DA, Hepler CD, Feldick HG. Clinical trial of topical erythromycin in inflammatory acne. Drug Intell Clin Pharm 1981;15:372-6.
55. Lesher JL Jr, Chalker DK, Smith JG Jr, Guenther LC, Ellis CN, Voorhees JJ, et al. An evaluation of a 2% erythromycin ointment in the topical therapy of acne vulgaris. J Am Acad Dermatol 1985;12:526-31.
56. Pochi PE, Bagatell FK, Ellis CN, Stoughton RB, Whitmore CG, Saatjian GD, et al. Erythromycin 2 percent gel in the treatment of acne vulgaris. Cutis 1988;41:132-6.
57. Dobson RL, Belknap BS. Topical erythromycin solution in acne. Results of a multiclinic trial. J Am Acad Dermatol 1980;3:478-82.
58. Mills O Jr, Thornsberry C, Cardin CW, Smiles KA, Leyden JJ. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002; 82:260-5.
59. Padilla RS, McCabe JM, Becker LE. Topical tetracycline hydrochloride vs. topical clindamycin phosphate in the treatment of acne: a comparative study. Int J Dermatol 1981;20:445-8.
60. Thomas DR, Raimer S, Smith EB. Comparison of topical erythromycin 1.5 percent solution versus topical clindamycin phosphate 1.0 percent solution in the treatment of acne vulgaris. Cutis 1982;29:624-5, 628-32.
61. Shalita AR, Smith EB, Bauer E. Topical erythromycin vs clindamycin therapy for acne. A multicenter, double-blind comparison. Arch Dermatol 1984;120:351-5.
62. Leyden JJ, Shalita AR, Saatjian GD, Sefton J. Erythromycin 2% gel in comparison with clindamycin phosphate 1% solution in acne vulgaris. J Am Acad Dermatol 1987;16:822-7.
63. McKenzie MW, Beck DC, Popovich NG. Topical clindamycin formulations for the treatment of acne vulgaris. An evaluation. Arch Dermatol 1981;117:630-4.
64. Kuhlman DS, Callen JP. A comparison of clindamycin phosphate 1 percent topical lotion and placebo in the treatment of acne vulgaris. Cutis 1986;38:203-6.
65. Becker LE, Bergstresser PR, Whiting DA, Clendenning WE, Dobson RL, Jordan WP, et al. Topical clindamycin therapy for acne vulgaris. A cooperative clinical study. Arch Dermatol 1981;117:482-5.
66. Ellis CN, Gammon WR, Stone DZ, Heezen-Wehner JL. A comparison of Cleocin T Solution, Cleocin T Gel, and placebo in the treatment of acne vulgaris. Cutis 1988;42: 245-7.
67. Glass D, Boorman GC, Stables GI, Cunliffe WJ, Goode K. A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatology 1999;199:242-7.
68. Mills OH Jr, Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol 1978;58:555-7.
69. Richter JR, Bousema MT, De Boulle KLV, Degreef HJ, Poli F. Efficacy of a fixed clindamycin phosphate 1.2%, tretinoin 0.025% gel formulation (Velac) in the topical control of facial acne lesions. J Dermatolog Treat 1998;9:81-90.
70. Zouboulis CC, Derumeaux L, Decroix J, Maciejewska-Udziela B, Cambazard F, Stuhlert A. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol 2000; 143:498-505.
71. Rietschel RL, Duncan SH. Clindamycin phosphate used in combination with tretinoin in the treatment of acne. Int J Dermatol 1983;22:41-3.
72. Chalker DK, Shalita A, Smith JG Jr, Swann RW. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 1983;9:933-6.
73. Tschen EH, Katz HI, Jones TM, Monroe EW, Kraus SJ, Connolly MA, et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis 2001;67:165-9.
74. Leyden JJ, Hickman JG, Jarratt MT, Stewart DM, Levy SF. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 2001;5:37-42.
75. Lookingbill DP, Chalker DK, Lindholm JS, Katz HI, Kempers SE, Huerter CJ, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997;37:590-5.
76. Shalita AR. Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis 1981;28:556-8, 561.
77. Cunliffe WJ, Holland KT. Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Derm Venereol Suppl (Stockh) 1989;143:31-4.
78. Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Derm Venereol Suppl (Stockh) 1989;143:35-9.
79. Hjorth N, Graupe K. Azelaic acid for the treatment of acne. A clinical comparison with oral tetracycline. Acta Derm Venereol Suppl (Stockh) 1989;143:45-8.
80. Elstein W. Topical deodorized polysulfides. Broadscope acne therapy. Cutis 1981;28:468-72.
81. Hurley HJ, Shelley WB. Special topical approach to the treatment of acne. Suppression of sweating with aluminum chloride in an anhydrous formulation. Cutis 1978;22: 696-703.
82. Hjorth N, Storm D, Dela K. Topical anhydrous aluminum chloride formulation in the treatment of acne vulgaris: a double-blind study. Cutis 1985;35:499-500.
83. Cochran RJ, Tucker SB, Flannigan SA. Topical zinc therapy for acne vulgaris. Int J Dermatol 1985;24:188-90.
84. Stainforth J, MacDonald-Hull S, Papworth-Smith JW, Eady EA. A single-blind comparison of topical erythromycin/zinc lotion and oral minocycline in the treatment of acne vulgaris. J Dermatolog Treat 1993;4:119-22.
85. Bojar RA, Eady EA, Jones CE, Cunliffe WJ, Holland KT. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994;130:329-36.
86. Thiboutot D. New treatments and therapeutic strategies for acne. Arch Fam Med 2000;9:179-87.
87. Lebrun CM. Rosac cream with sunscreens (sodium sulfacetamide 10% and sulfur 5%). Skinmed 2004;3:92.
88. Tarimci N, Sener S, Kilinc T. Topical sodium sulfacetamide/sulfur lotion. J Clin Pharm Ther 1997;22:301.
89. Lane P, Williamson DM. Treatment of acne vulgaris with tetracycline hydrochloride: a double-blind trial with 51 patients. Br Med J 1969;2:76-9.
90. Smith JG Jr, Chalker DK, Wehr RF. The effectiveness of topical and oral tetracycline for acne. South Med J 1976;69: 695-7.
91. Gratton D, Raymond GP, Guertin-Larochelle S, Maddin SW, Leneck CM, Warner J, et al. Topical clindamycin versus systemic tetracycline in the treatment of acne. Results of a multiclinic trial. J Am Acad Dermatol 1982;7:50-3.
92. Katsambas A, Towarky AA, Stratigos J. Topical clindamycin phosphate compared with oral tetracycline in the treatment of acne vulgaris. Br J Dermatol 1987;116:387-91.
93. Braathen LR. Topical clindamycin versus oral tetracycline and placebo in acne vulgaris. Scand J Infect Dis Suppl 1984; 43:71-5.
94. Anderson RL, Cook CH, Smith DE. The effect of oral and topical tetracycline on acne severity and on surface lipid composition. J Invest Dermatol 1976;66:172-7.
95. Blaney DJ, Cook CH. Topical use of tetracycline in the treatment of acne: a double-blind study comparing topical and oral tetracycline therapy and placebo. Arch Dermatol 1976;112:971-3.
96. Rapaport M, Puhvel SM, Reisner RM. Evaluation of topical erythromycin and oral tetracycline in acne vulgaris. Cutis 1982;30:122-6, 130, 132-5.
97. Norris JF, Hughes BR, Basey AJ, Cunliffe WJ. A comparison of the effectiveness of topical tetracycline, benzoyl-peroxide gel and oral oxytetracycline in the treatment of acne. Clin Exp Dermatol 1991;16:31-3.
98. Sauer GC. Safety of long-term tetracycline therapy for acne. Arch Dermatol 1976;112:1603-5.
99. Baer RL, Leshaw SM, Shalita AR. High-dose tetracycline therapy in severe acne. Arch Dermatol 1976;112:479-81.
100. Plewig G, Petrozzi JW, Berendes U. Double-blind study of doxycycline in acne vulgaris. Arch Dermatol 1970;101:435-8.
101. Harrison PV. A comparison of doxycycline and minocycline in the treatment of acne vulgaris. Clin Exp Dermatol 1988; 13:242-4.
102. Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139:459-64.
103. Hersle K, Gisslen H. Minocycline in acne vulgaris: a doubleblind study. Curr Ther Res Clin Exp 1976;19:339-42.
104. Sheehan-Dare RA, Papworth-Smith J, Cunliffe WJ. A doubleblind comparison of topical clindamycin and oral minocycline in the treatment of acne vulgaris. Acta Derm Venereol 1990;70:534-7.
105. Samuelson JS. An accurate photographic method for grading acne: initial use in a double-blind clinical comparison of minocycline and tetracycline. J Am Acad Dermatol 1985; 12:461-7.
106. Poliak SC, DiGiovanna JJ, Gross EG, Gantt G, Peck GL. Minocycline-associated tooth discoloration in young adults. JAMA 1985;254:2930-2.
107. Goulden V, Glass D, Cunliffe WJ. Safety of long-term highdose minocycline in the treatment of acne. Br J Dermatol 1996;134:693-5.
108. Gammon WR, Meyer C, Lantis S, Shenefelt P, Reizner G, Cripps DJ. Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. A doubleblind study. J Am Acad Dermatol 1986;14:183-6.
109. Al-Mishari MA. Clinical and bacteriological evaluation of tetracycline and erythromycin in acne vulgaris. Clin Ther 1987;9:273-80.
110. Parsad D, Pandhi R, Nagpal R, Negi KS. Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris. J Dermatol 2001;28:1-4.
111. Christian GL, Krueger GG. Clindamycin vs placebo as adjunctive therapy in moderately severe acne. Arch Dermatol 1975; 111:997-1000.
112. Cunliffe WJ, Cotterill JA. Clindamycin as an alternative to tetracycline in severe acne vulgaris. Practitioner 1973;210:

698-700.

113. Poulos ET, Tedesco FJ. Acne vulgaris: double-blind trial comparing tetracycline and clindamycin. Arch Dermatol 1976;112:974-6.
114. Panzer JD, Poche W, Meek TJ, Derbes VJ, Atkinson W. Acne treatment: a comparative efficacy trial of clindamycin and tetracycline. Cutis 1977;19:109-11.
115. Stoughton RB, Cornell RC, Gange RW, Walter JF. Doubleblind comparison of topical 1 percent clindamycin phosphate

(Cleocin T) and oral tetracycline 500 mg/day in the treatment

of acne vulgaris. Cutis 1980;26:424-5, 429.

116. Macdonald RH, Macconnell LE, Dunsmore IR. Trimethoprimsulphamethoxazole versus placebo in acne vulgaris. Br J Clin Pract 1972;26:97-8.
117. Hersle K. Trimethoprim-sulphamethoxazole in acne vulgaris. A double-blind study. Dermatologica 1972;145:187-91.
118. Cotterill JA, Cunliffe WJ, Forster RA, Williamson DM, Bulusu L. A comparison of trimethoprim-sulphamethoxazole with oxytetracycline in acne vulgaris. Br J Dermatol 1971;84: 366-9.
119. Gibson JR, Darley CR, Harvey SG, Barth J. Oral trimethoprim versus oxytetracycline in the treatment of inflammatory acne vulgaris. Br J Dermatol 1982;107:221-4.
120. Bottomley WW, Cunliffe WJ. Oral trimethoprim as a third-line antibiotic in the management of acne vulgaris. Dermatology 1993;187:193-6.
121. Miller YW, Eady EA, Lacey RW, Cove JH, Joanes DN, Cunliffe WJ. Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J Antimicrob Chemother 1996;38:829-37.
122. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997;37:746-54.
123. Olson WH, Lippman JS, Robisch DM. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris. Int J Fertil Womens Med 1998;43: 286-90.
124. Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD. A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril 2001;76:461-8.
125. Leyden J, Shalita A, Hordinsky M, Swinyer L, Stanczyk FZ, Weber ME. Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial. J Am Acad Dermatol 2002;47:399-409.
126. Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M, Weber ME. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception 1999;60: 255-62.
127. Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001;203:38-44.
128. Rosen MP, Breitkopf DM, Nagamani M. A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. Am J Obstet Gynecol 2003;188:1158-60.
129. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne

treatment. Cutis 2004;74:123-30.

130. Huber J, Walch K. Treating acne with oral contraceptives: use of lower doses. Contraception 2006;73:23-9.
131. Goodfellow A, Alaghband-Zadeh J, Carter G, Cream JJ, Holland S, Scully J, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol 1984;

111:209-14.

132. Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol 1986;115:227-32.
133. Hatwal A, Bhatt RP, Agrawal JK, Singh G, Bajpai HS. Spironolactone and cimetidine in treatment of acne. Acta Derm Venereol 1988;68:84-7.
134. Greenwood R, Brummitt L, Burke B, Cunliffe WJ. Acne: double blind clinical and laboratory trial of tetracycline, oestrogencyproterone acetate, and combined treatment. Br Med J (Clin Res Ed) 1985;291:1231-5.
135. Miller JA, Wojnarowska FT, Dowd PM, Ashton RE, O’Brien TJ, Griffiths WA, et al. Anti-androgen treatment in women with acne: a controlled trial. Br J Dermatol 1986;114:705-16.
136. Fugere P, Percival-Smith RK, Lussier-Cacan S, Davignon J, Farquhar D. Cyproterone acetate/ethinyl estradiol in the treatment of acne. A comparative dose-response study of the estrogen component. Contraception 1990;42:225-34.
137. Nader S, Rodriguez-Rigau LJ, Smith KD, Steinberger E. Acne and hyperandrogenism: impact of lowering androgen levels with glucocorticoid treatment. J Am Acad Dermatol 1984; 11:256-9.
138. Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol 2006; 54:644-6.
139. Goldstein JA, Socha-Szott A, Thomsen RJ, Pochi PE, Shalita AR, Strauss JS. Comparative effect of isotretinoin and etretinate on acne and sebaceous gland secretion. J Am Acad Dermatol 1982;6:760-5.
140. King K, Jones DH, Daltrey DC, Cunliffe WJ. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol 1982;107:583-90.
141. Peck GL, Olsen TG, Butkus D, Pandya M, Arnaud-Battandier J, Gross EG, et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 1982;6:735-45.
142. Strauss JS, Stranieri AM. Changes in long-term sebum production from isotretinoin therapy. J Am Acad Dermatol 1982;6:751-6.
143. Jones DH, King K, Miller AJ, Cunliffe WJ. A dose-response study of I3-cis-retinoic acid in acne vulgaris. Br J Dermatol 1983;108:333-43.
144. Strauss JS, Rapini RP, Shalita AR, Konecky E, Pochi PE, Comite H, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984;10:490-6.
145. Lester RS, Schachter GD, Light MJ. Isotretinoin and tetracycline in the management of severe nodulocystic acne. Int J Dermatol 1985;24:252-7.
146. Chivot M, Midoun H. Isotretinoin and acne—a study of relapses. Dermatologica 1990;180:240-3.
147. Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris—10 years later: a safe and successful treatment. Br J Dermatol 1993;129:292-6.
148. Lehucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 1993;186:123-8.
149. Stainforth JM, Layton AM, Taylor JP, Cunliffe WJ. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 1993; 129:297-301.
150. Goulden V, Clark SM, McGeown C, Cunliffe WJ. Treatment of acne with intermittent isotretinoin. Br J Dermatol 1997;137: 106-8.
151. Strauss JS, Leyden JJ, Lucky AW, Lookingbill DP, Drake LA, Hanifin JM, et al. A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne. J Am Acad Dermatol 2001;45:187-95.
152. McElwee NE, Schumacher MC, Johnson SC, Weir TW, Greene SL, Scotvold MJ, et al. An observational study of isotretinoin recipients treated for acne in a health maintenance organization. Arch Dermatol 1991;127:341-6.
153. Strauss JS, Leyden JJ, Lucky AW, Lookingbill DP, Drake LA, Hanifin JM, et al. Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: A randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol 2001;45: 196-207.
154. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313:837-41.
155. Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992;26: 599-606.
156. Zech LA, Gross EG, Peck GL, Brewer HB. Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin. A prospective study. Arch Dermatol 1983;119: 987-93.
157. Bershad S, Rubinstein A, Paterniti JR, Le NA, Poliak SC, Heller B, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985;313: 981-5.
158. Leachman SA, Insogna KL, Katz L, Ellison A, Milstone LM. Bone densities in patients receiving isotretinoin for cystic acne. Arch Dermatol 1999;135:961-5.
159. Goldsmith LA, Bolognia JL, Callen JP, Chen SC, Feldman SR, Lim HW, et al. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol 2004;50:900-6. Erratum in J Am Acad Dermatol 2004;51:348.
160. Myhill JE, Leichtman SR, Burnett JW. Self-esteem and social assertiveness in patients receiving isotretinoin treatment for cystic acne. Cutis 1988;41:171-3.
161. Rubinow DR, Peck GL, Squillace KM, Gantt GG. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol 1987;17:25-32.
162. Hull SM, Cunliffe WJ, Hughes BR. Treatment of the depressed and dysmorphophobic acne patient. Clin Exp Dermatol 1991; 16:210-1.
163. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000;136:1231-6.
164. Marqueling AL, Zane LT. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 2005;24:92-102.
165. Chia CY, Lane W, Chibnall J, Allen A, Siegfried E. Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study. Arch Dermatol 2005;141: 557-60.
166. Lehucher-Ceyrac D, de La Salmoniere P, Chastang C, Morel P. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 1999;198:278-83.
167. White GM, Chen W, Yao J, Wolde-Tsadik G. Recurrence rates after the first course of isotretinoin. Arch Dermatol 1998;134: 376-8.
168. Levine RM, Rasmussen JE. Intralesional corticosteroids in the treatment of nodulocystic acne. Arch Dermatol 1983;119: 480-1.
169. Potter RA. Intralesional triamcinolone and adrenal suppression in acne vulgaris. J Invest Dermatol 1971;57: 364-70.
170. Kim SW, Moon SE, Kim JA, Eun HC. Glycolic acid versus Jessner’s solution: which is better for facial acne patients? A randomized prospective clinical trial of split-face model therapy. Dermatol Surg 1999;25:270-3.
171. Wang CM, Huang CL, Hu CT, Chan HL. The effect of glycolic acid on the treatment of acne in Asian skin. Dermatol Surg 1997;23:23-9.
172. Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg 1999;25: 18-22.
173. Pepall LM, Cosgrove MP, Cunliffe WJ. Ablation of whiteheads by cautery under topical anaesthesia. Br J Dermatol 1991;125: 256-9.
174. Bassett IB, Pannowitz DL, Barnetson RS. A comparative study of tea-tree oil versus benzoylperoxide in the treatment of acne. Med J Aust 1990;153:455-8.
175. Paranjpe P, Kulkarni PH. Comparative efficacy of four Ayurvedic formulations in the treatment of acne vulgaris: a double-blind randomised placebo-controlled clinical evaluation. J Ethnopharmacol 1995;49:127-32.
176. Lalla JK, Nandedkar SY, Paranjape MH, Talreja NB. Clinical trials of ayurvedic formulations in the treatment of acne vulgaris. J Ethnopharmacol 2001;78:99-102.
177. Ellerbroek WC. Hypotheses toward a unified field theory of human behavior with clinical application to acne vulgaris. Perspect Biol Med 1973;16:240-62.
178. Hughes H, Brown BW, Lawlis GF, Fulton JE Jr. Treatment of acne vulgaris by biofeedback relaxation and cognitive imagery. J Psychosom Res 1983;27:185-91.
179. Bett DG, Morland J, Yudkin J. Sugar consumption in acne vulgaris and seborrhoeic dermatitis. Br Med J 1967;3: 153-5.
180. Fulton JE Jr, Plewig G, Kligman AM. Effect of chocolate on acne vulgaris. JAMA 1969;210:2071-4.

New insights into the management of acne: anupdate from the Global Alliance to ImproveOutcomes in Acne group. 2016

1. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49(Suppl):S1-37.
2. Gollnick H, Finlay AY, Shear N, Global Alliance to Improve Outcomes in Acne. Can we describe acne as a chronic disease? If so, how and when? Am J Clin Dermatol 2008;9:279-84.
3. Centers for Disease Control and Prevention. Classifications of diseases and functioning and disability. In: Classifications of diseases and functioning and disability. Vol 2008. National Center for Health Statistics; 2001 definition of disability reference. Available at http://www.cdc.gov/nchs/icd9.htm. Accessed February 23, 2009.
4. O’Halloran J, Miller GC, Britt H. Defining chronic conditions for primary care with ICPC-2. Fam Pract 2004;21:381-6. 5. Niemeier V, Kupfer J, Demmelbauer-Ebner M, Stangier U, Effendy I, Gieler U. Coping with acne vulgaris: evaluation of the chronic skin disorder questionnaire in patients with acne. Dermatology 1998;196:108-15.
5. Thiboutot DM, Lookingbill DP. Acne: acute or chronic disease? J Am Acad Dermatol 1995;32(Suppl):S2-5.
6. Goulden V, McGeown CH, Cunliffe WJ. The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals. Br J Dermatol 1999;141:297-300.
7. Tan J. The Canadian acne epidemiological survey: baseline demographics and interim analysis [abstract]. J Am Acad Dermatol 2004;50:15.
8. James WD. Clinical practice: acne. N Engl J Med 2005;352: 1463-72.
9. Kellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol 1999;140:273-82.
10. Cunliffe WJ. Acne and unemployment. Br J Dermatol 1986; 115:386.
11. Zhang JZ, Li LF, Tu YT, Zheng J. A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. J Dermatolog Treat 2004;15:372-8.
12. Leyden J, Thiboutot DM, Shalita AR, Webster G, Washenik K, Strober BE, et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol 2006;142:605-12.
13. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Kerrouche N, Arsonnaud S, et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol 2006;142:597-602.
14. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol 1999;41:577-80.
15. Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008;58:56-9.
16. Poli F, Pernet AM, Verschoore M. Epidemiological study on adult acne [abstract]. J Am Acad Dermatol 2007;56: AB13.
17. Poli F, Dre´no B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol 2001;15:541-5.
18. Kligman A. Postadolescent acne in women. Cutis 1992;48: 218-22.
19. Till AE, Goulden V, Cunliffe WJ, Holland KT. The cutaneous microflora of adolescent, persistent and late-onset acne patients does not differ. Br J Dermatol 2000;142:885-92.
20. Plewig G, Kligman A. Acne and rosacea. 3rd ed. New York: Springer; 2000.
21. Cunliffe WJ, Gollnick HPM. Acne: diagnosis and management. London: Taylor and Francis; 2001.
22. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003;121:20-7.
23. Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect Immun 1995;63:3158-65.
24. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002;169: 1535-41.
25. Kapetanovic R, Cavaillon JM. Early events in innate immunity in the recognition of microbial pathogens. Expert Opin Biol Ther 2007;7:907-18.
26. Jugeau S, Tenaud I, Knol AC, Jarrousse V, Quereux G, Khammari A, et al. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol 2005;153:1105-13.
27. Kang S, Cho S, Chung JH, Hammerberg C, Fisher GJ, Voorhees JJ. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol 2005;166:1691-9.
28. Czernielewski J, Michel S, Bouclier M, Baker M, Hensby JC. Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne. J Eur Acad Dermatol Venereol 2001;15(Suppl):5-12.
29. Liu PT, Phan J, Tang D, Kanchanapoomi M, Hall B, Krutzik SR, et al. CD209(1) macrophages mediate host defense against Propionibacterium acnes. J Immunol 2008;180:4919-23.
30. Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S, et al. Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol 2006; 126:2002-9.
31. Smith TM, Cong Z, Gilliland KL, Clawson GA, Thiboutot DM. Insulin-like growth factor-1 induces lipid production in human SEB-1 sebocytes via sterol response element-binding protein-1. J Invest Dermatol 2006;126:1226-32.
32. Zouboulis CC, Baron JM, Bohm M, Kippenberger S, Kurzen H, Reichrath J, et al. Frontiers in sebaceous gland biology and pathology. Exp Dermatol 2008;17:542-51.
33. Zouboulis CC, Chen WC, Thornton MJ, Qin K, Rosenfield R. Sexual hormones in human skin. Horm Metab Res 2007;39: 85-95.
34. Zouboulis CC. The human skin as a hormone target and an endocrine gland. Hormones (Athens, Greece) 2004;3:9-26.
35. Wille JJ, Kydonieus A. Palmitoleic acid isomer (C16:1delta6) in human skin sebum is effective against gram-positive bacteria. Skin Pharmacol Appl Skin Physiol 2003;16:176-87.
36. Georgel P, Crozat K, Lauth X, Makrantonaki E, Seltmann H, Sovath S, et al. A toll-like receptor 2-responsive lipid effector pathway protects mammals against skin infections with gram-positive bacteria. Infect Immun 2005;73:4512-21.
37. Boehm KD, Yun JK, Strohl KP, Elmets CA. Messenger RNAs for the multifunctional cytokines interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor-alpha are present in adnexal tissues and in dermis of normal human skin. Exp Dermatol 1995;4:335-41.
38. Zouboulis CC, Bohm M. Neuroendocrine regulation of sebocytesea pathogenetic link between stress and acne. Exp Dermatol 2004;13(Suppl):31-5.
39. Ziegler CG, Krug AW, Zouboulis CC, Bornstein SR. Corticotropin releasing hormone and its function in the skin. Horm Metab Res 2007;39:106-9.
40. Slominski AT, Botchkarev V, Choudhry M, Fazal N, Fechner K, Furkert J, et al. Cutaneous expression of CRH and CRH-R: is there a ‘‘skin stress response system?’’ Ann N Y Acad Sci 1999;885:287-311.
41. Toyoda M, Morohashi M. New aspects in acne inflammation. Dermatology 2003;206:17-23.
42. Bohm M, Schiller M, Stander S, Seltmann H, Li Z, Brzoska T, et al. Evidence for expression of melanocortin-1 receptor in human sebocytes in vitro and in situ. J Invest Dermatol 2002; 118:533-9.
43. Zhang L, Anthonavage M, Huang Q, Li WH, Eisinger M. Proopiomelanocortin peptides and sebogenesis. Ann N Y Acad Sci 2003;994:154-61.
44. Zouboulis CC, Seltmann H, Hiroi N, Chen W, Young M, Oeff M, et al. Corticotropin-releasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci U S A 2002;99:7148-53.
45. Thielitz A, Ansorge S, Bank U, Tager M, Wrenger S, Gollhick H, et al. The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases. Front Biosci 2008;13:2364-75.
46. Zouboulis CC. Isotretinoin revisited: pluripotent effects on human sebaceous gland cells. J Invest Dermatol 2006;126: 2154-6.
47. Ottaviani M, Alestas T, Flori E, Mastrofrancesco A, Zouboulis CC, Picardo M. Peroxidated squalene induces the production of inflammatory mediators in HaCaT keratinocytes: a possible role in acne vulgaris. J Invest Dermatol 2006;126:2430-7.
48. Zouboulis CC. Leukotrien-antagonisten bie atopischen Erkrankungen und Akne. Akt Dermatol 2003;29:419-25.
49. Zouboulis CC, Saborowski A, Boschnakow A. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology 2005;210:36-8.
50. Alestas T, Ganceviciene R, Fimmel S, Muller-Decker K, Zouboulis CC. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med 2006;84:75-87.
51. Papakonstantinou E, Aletras AJ, Glass E, Tsogas P, Dionyssopoulos A, Adjaye J, et al. Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol 2005;125:673-84.
52. Lesens O, Haus-Cheymol R, Dubrous P, Verret C, Spiegel A, Bonnet R, et al. Methicillin-susceptible, doxycycline-resistant Staphylococcus aureus, Cote d’Ivoire. Emerg Infect Dis 2007; 13:488-90.
53. Raum E, Lietzau S, von Baum H, Marre R, Brenner H. Changes in Escherichia coli resistance patterns during and after antibiotic therapy: a longitudinal study among outpatients in Germany. Clin Microbiol Infect 2008;14:41-8.
54. Oprica C, Nord CE. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes. Clin Microbiol Infect 2005;11:204-13.
55. Eady EA, Cove JH. Topical antibiotic therapy: current status and future prospects. Drugs Exp Clin Res 1990;16:423-33.
56. Dre´no B, Bettoli V, Ochsendorf F, Perez-Lopez M, Mobacken H, Degreef H, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol 2004;14:391-9.
57. Del Rosso JQ, Leyden JJ. Status report on antibiotic resistance: implications for the dermatologist. Dermatol Clin 2007;25:127-32.
58. Nord CE, Oprica C. Antibiotic resistance in Propionibacterium acnes: microbiological and clinical aspects. Anaerobe 2006; 12:207-10.
59. Eady EA, Bojar RA, Jones CE, Cove JH, Holland KT, Cunliffe WJ. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol 1996;134:107-13.
60. Eady EA, Farmery MR, Ross JI, Cove JH, Cunliffe WJ. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br J Dermatol 1994;131:331-6.
61. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003;4:813-31.
62. Oprica C, Lofmark S, Lund B, Edlund C, Emtestam L, Nord CE. Genetic basis of resistance in Propionibacterium acnes strains isolated from diverse types of infection in different European countries. Anaerobe 2005;11:137-43.
63. Oprica C, Emtestam L, Lapins J, Borglund E, Nyberg F, Stenlund K, et al. Antibiotic-resistant Propionibacterium acnes on the skin of patients with moderate to severe acne in Stockholm. Anaerobe 2004;10:155-64.
64. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. Comparative in vitro activities of retapamulin (SB-275833) against 141 clinical isolates of Propionibacterium spp., including 117 P acnes isolates. Antimicrob Agents Chemother 2006;50:379-81.
65. Mills O Jr, Thornsberry C, Cardin CW, Smiles KA, Leyden JJ. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002;82:260-5.
66. Ozolins M, Eady EA, Avery AJ, Cunliffe WJ, Po AI, O’Neill C, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomized controlled trial. Lancet 2004; 364:2188-95.
67. Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983;8:41-5.
68. Eady EA. Bacterial resistance in acne. Dermatology 1998;196: 59-66.
69. Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 1998;169: 259-61.
70. Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003;148:467-78.
71. Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 2003;139:467-71.
72. Margolis DJ, Bowe WP, Hoffstad O, Berlin JA. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol 2005;141:1132-6.
73. Levy PY, Fenollar F, Stein A, Borrione F, Cohen E, Lebail B, et al. Propionibacterium acnes postoperative shoulder arthritis: an emerging clinical entity. Clin Infect Dis 2008;46: 1884-6.
74. Berthelot P, Carricajo A, Aubert G, Akhavan H, Gazielly D, Lucht F. Outbreak of postoperative shoulder arthritis due to Propionibacterium acnes infection in nondebilitated patients. Infect Control Hosp Epidemiol 2006;27:987-90.
75. Delahaye F, Fol S, Celard M, Vandenesch F, Beaune J, Bozio A, et al. Propionibacterium acnes infective endocarditis: study of 11 cases and review of literature [French]. Arch Mal Coeur Vaiss 2005;98:1212-8.
76. Bagyalakshmi R, Madhavan HN, Therese KL. Development and application of multiplex polymerase chain reaction for the etiological diagnosis of infectious endophthalmitis. J Postgrad Med 2006;52:179-82.
77. Chanet V, Romaszko JP, Rolain JM, Beytout J. Propionibacterium acnes adenitis [French]. Presse Med 2005;34:1005-6.
78. Jakab E, Zbinden R, Gubler J, Ruef C, von Graevenitz A, Krause M. Severe infections caused by Propionibacterium acnes: an underestimated pathogen in late postoperative

infections. Yale J Biol Med 1996;69:477-82.

80. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003;206:54-6.
81. Tan HH, Goh CL, Yeo MG, Tan ML. Antibiotic sensitivity of Propionibacterium acnes isolates from patients with acne vulgaris in a tertiary dermatological referral center in Singapore. Ann Acad Med Singapore 2001;30:22-5.
82. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001;357:1851-3.
83. Ross JI, Snelling AM, Eady EA, Cove JH, Cunliffe WJ, Leyden JJ, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the USA,

Japan and Australia. Br J Dermatol 2001;144:339-46.

84. Espersen F. Resistance to antibiotics used in dermatological practice. Br J Dermatol 1998;139(Suppl):4-8.
85. Bhambri S, Del Rosso JQ, Desai A. Oral trimethoprim/sulfamethoxazole in the treatment of acne vulgaris. Cutis 2007;79: 430-4.
86. Matsuzaki K, Omika K, Hasegawa M, Sato Y, Kobayashi I. Antibacterial activity of nadifloxacin against Staphylococcus and Propionibacterium isolated from patients with dermatological infections [French]. Jpn J Antibiot 2006;59:316-20.
87. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed 2003;2:234-45.
88. Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol 1986;86:449-53.
89. Akamatsu H, Nishijima S, Takahashi M, Ushijima T, Asada Y. Effects of subminimal inhibitory concentrations of erythromycin, tetracycline, clindamycin, and minocycline on the neutrophil chemotactic factor production in Propionibacterium acnes biotypes 1-5. J Dermatol 1991;18:247-51.
90. Akamatsu H, Asada M, Komura J, Asada Y, Niwa Y. Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline. Acta Derm Venereol 1992;72:178-9.
91. Weiss JS, Shavin JS. Topical retinoid and antibiotic combination therapy for acne management. J Drugs Dermatol 2004;3: 146-54.
92. Norris JF, Cunliffe WJ. A histological and immunocytochemical study of early acne lesions. Br J Dermatol 1988;118: 651-9.
93. Cunliffe WJ, Holland DB, Clark SM, Stables GI. Comedogenesis: some etiological, clinical and therapeutic strategies. Dermatology 2003;206:11-6.
94. Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol 2007;21: 747-53.
95. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003; 49(Suppl):S200-10.
96. Mills OH Jr, Marples RR, Kligman AM. Acne vulgaris: oral therapy with tetracycline and topical therapy with vitamin A. Arch Dermatol 1972;106:200-3.
97. Christiansen JV, Gadborg E, Ludvigsen K, Meier CH, Norholm A, Pedersen D, et al. Topical vitamin A acid (Airol) and systemic oxytetracycline in the treatment of acne vulgaris: a controlled clinical trial. Dermatologica 1974;149:121-8.
98. Hurwitz S. The combined effect of vitamin A acid and benzoyl peroxide in the treatment of acne. Cutis 1976;17: 585-90.
99. Handojo I. The combined use of topical benzoyl peroxide and tretinoin in the treatment of acne vulgaris. Int J Dermatol 1979;18:489-96.
100. Mills OH Jr, Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol 1978;58:555-7.
101. Kligman AM, Mills OH, McGinley KJ, Leyden JJ. Acne therapy with tretinoin in combination with antibiotics. Acta Derm Venereol Suppl (Stockh) 1975;74:111-5.
102. Rietschel RL, Duncan SH. Clindamycin phosphate used in combination with tretinoin in the treatment of acne. Int J Dermatol 1983;22:41-3.
103. Swinyer LJ, Swinyer TA, Britt MR. Topical agents alone in acne: a blind assessment study. JAMA 1980;243:1640-3.
104. Shalita AR, Rafal ES, Anderson DN, Yavel R, Landow S, Lee WL. Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Cutis 2003;72: 167-72.
105. Wolf JE Jr, Kaplan D, Kraus SJ, Loven KH, Rist T, Swinyer LJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003;49(Suppl):S211-7.
106. Tanghetti E, Dhawan S, Torok H, Kircik L. Tazarotene 0.1% cream plus clindamycin 1% gel versus tretinoin 0.025% gel plus clindamycin 1% in the treatment of facial acne vulgaris. In: Tazarotene 0.1% cream plus clindamycin 1% gel versus tretinoin 0.025% gel plus clindamycin 1% in the treatment of facial acne vulgaris, Dermatol Online J 2007;13:1.
107. Tanghetti E. Comparison of the tolerability and efficacy of tazarotene 0.1% cream used in a combination regimen with clindamycin 1% gel versus tretinoin 0.025% gel used in a combination regimen with clindamycin 1% gel for the treatment of acne vulgaris [abstract]. J Am Acad Dermatol,

2007;56:AB14.

108. Brand B, Gilbert R, Baker MD, Poncet M, Greenspan A, Georgeian K, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol 2003;49(Suppl):S227-32.
109. Dosik JS, Gilbert RD, Arsonnaud S. Cumulative irritancy comparison of topical retinoid and antimicrobial combination therapies. Skinmed 2006;5:219-23.
110. Cunliffe WJ, Meynadier J, Alirezai M, George SA, Coutts I, Roseeuw DI, et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol 2003;49(Suppl):S218-26.
111. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S, Kang S, et al. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed 2005;4:138-46.
112. Campbell JL Jr, Weiss JS. The results of the MORE trial: overview. Cutis 2006;78:5-11.
113. Campo MS, Zulaga A, Escobar P. A comparative study on the effectiveness of lymecycline and adapalene versus minocycline and adapalene in the treatment of acne vulgaris. Proceedings of the 20th World Congress of Dermatology. Paris, France, July 1-5, 2002. P0005.
114. Shalita A. Topical tazarotene: the BEST (balancing efficacy, speed, and tolerability) in acne trial. Cutis 2004;74:4-8.
115. Rodriguez D, Davis MW. The BEST study: results according to prior treatment. Cutis 2003;71:27-34.
116. Weiss J, Shavin J, Davis MW. Overall results of the BEST study following treatment of patients with mild to moderate acne. Cutis 2003;71:10-7.
117. Shavin J, Weiss J. Implications of the BEST study. Cutis 2003; 71:35-6.
118. Weiss J, Shavin J, Davis MW. Improving patient satisfaction and acne severity in patients with mild to moderate acne: the BEST study. Cutis 2003;71:3-4.
119. Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007;57:791-9.
120. Pariser DM, Westmoreland P, Morris A, Gold MH, Liu Y, Graeber M. Long-term safety and efficacy of a unique fixeddose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. J Drugs Dermatol 2007;6:899-905.
121. Zouboulis CC, Derumeaux L, Decroix J, Maciejewska-Udziela B, Cambazard F, Stuhlert A. A multicenter, single-blind, randomized comparison of a fixed clindamycin phosphate/-tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol 2000; 143:498-505.
122. Richter JR, Forstrom LR, Kiistala UO, Jung EG. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol 1998;11:227-33.
123. Queille-Roussel C, Poncet M, Mesaros S, Clucas A, Baker M, Soloff AM. Comparison of the cumulative irritation potential of adapalene gel and cream with that of erythromycin/tretinoin solution and gel and erythromycin/isotretinoin gel. Clin Ther 2001;23:205-12.
124. Gupta AK, Lynde CW, Kunynetz RA, Amin S, Choi K, Goldstein E. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. J Cutan Med Surg 2003;7:31-7.
125. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006;54:73-81.
126. Amblard P, Bazex A, Beylot C, Civatte J, Garrel J, Grupper C, et al. The association tretinoin-erythromycin base: a new topical treatment for acne; results of a multicentric trial on 347 cases (authors transl) [French]. Sem Hop 1980;56:911-5.
127. Draelos ZD, Tanghetti EA. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis 2002;69:20-9.
128. Tanghetti E, Abramovits W, Solomon B, Loven K, Shalita A. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, doubleblind, randomized parallel-group trial. J Drugs Dermatol 2006; 5:256-61.
129. Bowman S, Gold M, Nasir A, Vamvakias G. Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. J Drugs Dermatol 2005;4:611-8.
130. Del Rosso JQ. Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. J Drugs Dermatol 2007;6: 616-22.
131. Kircik L. Community-based trial results of combination clindamycin 1%ebenzoyl peroxide 5% topical gel plus tretinoin microsphere gel 0.04% or 0.1% or adapalene gel 0.1% in the treatment of moderate to severe acne. Cutis 2007;80:10-4.
132. Tenaud I, Khammari A, Dre´no B. In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol 2007;16:500-6.
133. Stein-Gold L, Tan J, Werschler W. Adapalene-benzoyl peroxide, a unique fixed dose combination gel for the treatment of acne: a North American, multicenter, randomized, doubleblind, controlled, phase III trial in 1,668 patients. Arch Dermatol. In press.
134. Yaroshinsky A, Leyden J. The safety and efficacy of clindamycin (1%), as clindamycin phosphate and tretinoin (0.025%) for the treatment of acne vulgaris: a combined analysis of results from six controlled safety and efficacy trials conducted in Europe [abstract]. J Am Acad Dermatol 2004;50: P23.
135. Korting HC, Braun-Falco O. Efficacy and tolerability of combined topical treatment of acne vulgaris with tretinoin and erythromycin in general practice. Drugs Exp Clin Res 1989;15: 447-51.
136. Kreusch J, Bextermoller R. Efficacy and tolerability of a topical erythromycin/tretinoin combination preparation in acne

treatment: post-marketing surveillance study involving over

6500 patients. Curr Med Res Opin 2000;16:1-7.

137. Ross EV. Acne, lasers, and light. Adv Dermatol 2005;21:1-32.
138. Cunliffe WJ, Goulden V. Phototherapy and acne vulgaris. Br J Dermatol 2000;142:855-6.
139. Young S, Bolton P, Dyson M, Harvey W, Diamantopoulos C. Macrophage responsiveness to light therapy. Lasers Surg Med 1989;9:497-505.
140. Taub AF. Procedural treatments for acne vulgaris. Dermatol Surg 2007;33:1005-26.
141. Shnitkind E, Yaping E, Geen S, Shalita AR, Lee WL. Antiinflammatory properties of narrow-band blue light. J Drugs Dermatol 2006;5:605-10.
142. Mariwalla K, Rohrer TE. Use of lasers and light-based therapies for treatment of acne vulgaris. Lasers Surg Med 2005;37: 333-42.
143. Elman M, Lebzelter J. Light therapy in the treatment of acne vulgaris. Dermatol Surg 2004;30:139-46.
144. Peng Q, Moan J, Warloe T, Nesland JM, Rimington C. Distribution and photosensitizing efficiency of porphyrins induced by application of exogenous 5-aminolevulinic acid in mice bearing mammary carcinoma. Int J Cancer 1992;52:433-43.
145. Ashkenazi H, Malik Z, Harth Y, Nitzan Y. Eradication of Propionibacterium acnes by its endogenic porphyrins after illumination with high intensity blue light. FEMS Immunol Med Microbiol 2003;35:17-24.
146. Horfelt C, Stenquist B, Larko O, Faergemann J, Wennberg AM. Photodynamic therapy for acne vulgaris: a pilot study of the dose-response and mechanism of action. Acta Derm Venereol 2007;87:325-9.
147. Yung A, Stables GI, Fernandez C, Williams J, Bojar RA, Goulden V. Microbiological effect of photodynamic therapy (PDT) in healthy volunteers: a comparative study using methyl aminolevulinate and hexyl aminolevulinate cream. Clin Exp Dermatol 2007;32:716-21.
148. Guffey JS, Wilborn J. In vitro bactericidal effects of 405-nm and 470-nm blue light. Photomed Laser Surg 2006;24: 684-8.
149. Seaton ED, Mouser PE, Charakida A, Alam S, Seidon PM, Chu AC. Investigation of the mechanism of action of nonablative pulsed-dye laser therapy in photorejuvenation and inflammatory acne vulgaris. Br J Dermatol 2006;155:748-55.
150. Bhardwaj SS, Rohrer TE, Arndt K. Lasers and light therapy for acne vulgaris. Semin Cutan Med Surg 2005;24:107-12.
151. Hongcharu W, Taylor CR, Chang Y, Aghassi D, Suthamjariya K, Anderson RR. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol 2000;115: 183-92.
152. Galderma LLP. Data on file.
153. Lloyd JR, Mirkov M. Selective photothermolysis of the sebaceous glands for acne treatment. Lasers Surg Med 2002;31: 115-20.
154. Leyden JJ, McGinley KJ. Effect of 13-cis-retinoic acid on sebum production and Propionibacterium acnes in severe nodulocystic acne. Arch Dermatol Res 1982;272:331-7.
155. Paithankar DY, Ross EV, Saleh BA, Blair MA, Graham BS. Acne treatment with a 1,450 nm wavelength laser and cryogen spray cooling. Lasers Surg Med 2002;31:106-14.
156. Shalita AR, Harthy Y, Elman M. Acne phototherapy using UV free high intensity narrow band blue lighte3 center clinical study. Proc SPIE 2001;4244:61-73. Available at: http://spie. org/x648.html?product_id=427830. Accessed February 23, 2009.
157. Elman M, Slatkine M, Harth Y. The effective treatment of acne vulgaris by a high-intensity, narrow band 405-420 nm light source. J Cosmet Laser Ther 2003;5:111-7.
158. Elman M, Lask G. The role of pulsed light and heat energy (LHE) in acne clearance. J Cosmet Laser Ther 2004;6:91-5.
159. Kawada A, Aragane Y, Kameyama H, Sangen Y, Tezuka T. Acne phototherapy with a high-intensity, enhanced, narrowband, blue light source: an open study and in vitro investigation. J Dermatol Sci 2002;30:129-35.
160. Tremblay JF, Sire DJ, Lowe NJ, Moy RL. Light-emitting diode 415 nm in the treatment of inflammatory acne: an openlabel, multicentric, pilot investigation. J Cosmet Laser Ther 2006;8:31-3.
161. Morton CA, Scholefield RD, Whitehurst C, Birch J. An open study to determine the efficacy of blue light in the treatment of mild to moderate acne. J Dermatolog Treat 2005;16: 219-23.
162. Omi T, Bjerring P, Sato S, Kawana S, Hankins RW, Honda M. 420 nm Intense continuous light therapy for acne. J Cosmet Laser Ther 2004;6:156-62.
163. Tzung TY, Wu KH, Huang ML. Blue light phototherapy in the treatment of acne. Photodermatol Photoimmunol Photomed 2004;20:266-9.
164. Papageorgiou P, Katsambas A, Chu A. Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris. Br J Dermatol 2000;142:973-8.
165. Gold MH, Rao J, Goldman MP, Bridges TM, Bradshaw VL, Boring MM, et al. A multicenter clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution. J Drugs Dermatol 2005;4:64-70.
166. Alexiades-Armenakas M. Laser-mediated photodynamic therapy. Clin Dermatol 2006;24:16-25.
167. Friedman PM, Jih MH, Kimyai-Asadi A, Goldberg LH. Treatment of inflammatory facial acne vulgaris with the 1450-nm diode laser: a pilot study. Dermatol Surg 2004;30:147-51.
168. Seaton ED, Charakida A, Mouser PE, Grace I, Clement RM, Chu AC. Pulsed-dye laser treatment for inflammatory acne vulgaris: randomized controlled trial. Lancet 2003;362:1347-52.
169. Webster GF. Laser treatment of acne. Lancet 2003;362:1342.
170. Orringer JS, Kang S, Hamilton T, Schumacher W, Cho S, Hammerberg C, et al. Treatment of acne vulgaris with a pulsed dye laser: a randomized controlled trial. JAMA 2004; 291:2834-9.
171. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. J Am Acad Dermatol 2006;54:647-51.
172. Nestor MS, Gold MH, Kauvar AN, Taub AF, Geronemus RG, Ritvo EC, et al. The use of photodynamic therapy in dermatology: results of a consensus conference. J Drugs Dermatol 2006;5:140-54.
173. Fritsch C, Homey B, Stahl W, Lehmann P, Ruzicka T, Sies H. Preferential relative porphyrin enrichment in solar keratosis upon topical application of delta-aminolevulinic acid methylester. Photochem Photobiol 1998;68:218-21.
174. Itoh Y, Ninomiya Y, Tajima S, Ishibashi A. Photodynamic therapy of acne vulgaris with topical delta-aminolevulinic acid and incoherent light in Japanese patients. Br J Dermatol 2001;144: 575-9.
175. Gold MH, Bradshaw VL, Boring MM, Bridges TM, Biron JA. Treatment of sebaceous gland hyperplasia by photodynamic therapy with 5-aminolevulinic acid and a blue light source or intense pulsed light source. J Drugs Dermatol 2004;3(Suppl): S6-9.
176. Goldman MP, Boyce SM. A single-center study of aminolevulinic acid and 417 NM photodynamic therapy in the treatment of moderate to severe acne vulgaris. J Drugs Dermatol 2003;2:393-6.
177. Gold MH, Biron JA, Boring M, Bridges TM, Bradshaw VL. Treatment of moderate to severe inflammatory acne vulgaris: photodynamic therapy with 5-aminolevulinic acid and a novel advanced fluorescence technology pulsed light source. J Drugs Dermatol 2007;6:319-22.
178. Taub AF. Photodynamic therapy for the treatment of acne: a pilot study. J Drugs Dermatol 2004;3(Suppl):S10-4.
179. Horfelt C, Funk J, Frohm-Nilsson M, Wiegleb Edstrom D, Wennberg AM. Topical methyl aminolevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. Br J Dermatol 2006;155:608-13.
180. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolevulinate: a blinded, randomized, controlled trial. Br J Dermatol 2006;154:969-76.
181. Yeung CK, Shek SY, Bjerring P, Yu CS, Kono T, Chan HH. A comparative study of intense pulsed light alone and its combination with photodynamic therapy for the treatment of facial acne in Asian skin. Lasers Surg Med 2007;39:1-6.
182. Taub AF. A comparison of intense pulsed light, combination radiofrequency and intense pulsed light, and blue light in photodynamic therapy for acne vulgaris. J Drugs Dermatol 2007;6:1010-6.
183. Haedersdal M, Togsverd-Bo K, Wiegell SR, Wulf HC. Longpulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: a randomized controlled trial. J Am Acad Dermatol 2008;58:387-94.
184. Sigurdsson V, Knulst AC, van Weelden H. Phototherapy of acne vulgaris with visible light. Dermatology 1997;194:256-60.
185. Nataloni R. Laser treatment comparable to oral antibiotics: 532 nm laser addresses multiple acne pathogens. In: Dermatology Times. Danvers (MA): Advanstar Communications; 2003.
186. Wilson F. Light-based therapies battle acne without side effects: response is quicker than with oral antibiotics; improvement is equivalent. In: Dermatology Times. Danvers (MA): Advanstar Communications. 2004.
187. Haedersdal M, Togsverd-Bo K, Wulf HC. Evidence-based review of lasers, light sources and photodynamic therapy in the treatment of acne vulgaris. J Eur Acad Dermatol Venereol 2008;22:267-78.
188. Stone AC. Facing up to acne. Pediatr Nurs 1982;8:229-34. 189. Thielitz A, Helmdach M, Ropke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol 2001;145:19-27.
189. Alirezai M, George SA, Coutts I, Roseeuw DI, Hachem JP, Kerrouche N, et al. Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol 2007;17:45-51.
190. Gould DJ, Cunliffe WJ. The long-term treatment of acne vulgaris. Clin Exp Dermatol 1978;3:249-52.
191. Weiss JS, Thiboutot DM, Hwa J, Liu Y, Graeber M. Long-term safety and efficacy study of adapalene 0.3% gel. J Drugs Dermatol 2008;7(Suppl):S24-8.
192. Bettoli V, Mantovani L, Borghi A. Adapalene 0.1% cream after oral isotretinoin: evaluation of the acne recurrence incidence. Rhodes: Medimond Monduzzi Editore International Proceedings, Division — 15th Congress of the European Academy of Dermatology and Venereology, 2006. Available at: http://www.medimond.com/proceedings/moreinfo/20061004.htm. Accessed February 23, 2009.
193. Bettoli V, Lombardi AR, Pazzaglia M, Virgili A. Isotretinoina ed acne grave: esperienza personale in tema di recidive dopo un lungo periodo di follow-up. G Ital Dermatol Venereol 1998; 133:333-6.
194. Cavicchini S, Caputo R. L’isotretinoina sistemica nella terapia delle diverse forme di acne: esperienza personale su indicazioni, schemi terapeutici e monitoraggio clinic e di laboratorio.

G Ital Dermatol Venereol 1996;131(Suppl):1-15.

196. Lehucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 1993;186:123-8.
197. Stainforth JM, Layton AM, Taylor JP, Cunliffe WJ. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 1993;129:297-301.
198. Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgarise10 years later: a safe and successful treatment. Br J Dermatol 1993;129:292-6.
199. Harms M, Masouye I, Radeff B. The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study. Dermatologica 1986;172:148-53.
200. Tanzi EL, Alster TS. Laser treatment of scars. Skin Therapy Lett 2004;9:4-7.
201. Goodman GJ. Management of post-acne scarring: what are the options for treatment? Am J Clin Dermatol 2000;1: 3-17.
202. Layton AM, Henderson CA, Cunliffe WJ. A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol 1994;19: 303-8.
203. Alster T, Zaulyanov L. Laser scar revision: a review. Dermatol Surg 2007;33:131-40.
204. Baum CL, Arpey CJ. Normal cutaneous wound healing: clinical correlation with cellular and molecular events. Dermatol Surg 2005;31:674-86.
205. Nouri K, Alster TS, Ballard CJ. Laser revision of scars. In: Laser revision of scars. Available at: http://www.emedicine.com/derm/topic519htm. Accessed February 23, 2009.
206. Holland DB, Jeremy AH, Roberts SG, Seukeran DC, Layton AM, Cunliffe WJ. Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar. Br J Dermatol 2004;150:72-81.
207. Jacob CI, Dover JS, Kaminer MS. Acne scarring: a classification system and review of treatment options. J Am Acad Dermatol 2001;45:109-17.
208. Dre´no B, Khammari A, Orain N, Noray C, Merial-Kieny C, Mery S, et al. ECCA grading scale: an original validated acne scar grading scale for clinical practice in dermatology. Dermatology 2007;214:46-51.
209. Goodman GJ, Baron JA. Postacne scarringea quantitative global scarring grading system. J Cosmet Dermatol 2006;5: 48-52.
210. Bhalla M, Thami GP. Microdermabrasion: reappraisal and brief review of literature. Dermatol Surg 2006;32:809-14.
211. Jacyk WK, Mpofu P. Adapalene gel 0.1% for topical treatment of acne vulgaris in African patients. Cutis 2001;68:48-54.
212. Lee JB, Chung WG, Kwahck H, Lee KH. Focal treatment of acne scars with trichloroacetic acid: chemical reconstruction of skin scars method. Dermatol Surg 2002;28:1017-21.
213. Tanzi EL, Alster TS. Comparison of a 1450-nm diode laser and a 1320-nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histologic study. Dermatol Surg 2004;30:152-7.
214. Sadick NS, Schecter AK. A preliminary study of utilization of the 1320-nm Nd:YAG laser for the treatment of acne scarring. Dermatol Surg 2004;30:995-1000.
215. Bellew SG, Lee C, Weiss MA, Weiss RA. Improvement of atrophic acne scars with a 1,320 nm Nd:YAG laser: retrospective study. Dermatol Surg 2005;31:1218-22.
216. Chan HH, Lam LK, Wong DS, Kono T, Trendell-Smith N. Use of 1,320 nm Nd:YAG laser for wrinkle reduction and the treatment of atrophic acne scarring in Asians. Lasers Surg Med 2004;34:98-103.
217. Carniol PJ, Vynatheya J, Carniol E. Evaluation of acne scar treatment with a 1450-nm midinfrared laser and 30% trichloroacetic acid peels. Arch Facial Plast Surg 2005;7:251-5.
218. Alster TS, McMeekin TO. Improvement of facial acne scars by the 585 nm flashlamp-pumped pulsed dye laser. J Am Acad Dermatol 1996;35:79-81.
219. Alster TS. Improvement of erythematous and hypertrophic scars by the 585-nm flashlamp-pumped pulsed dye laser. Ann Plast Surg 1994;32:186-90.
220. Dierickx C, Goldman MP, Fitzpatrick RE. Laser treatment of erythematous/hypertrophic and pigmented scars in 26 patients. Plast Reconstr Surg 1995;95:84-92.
221. Alster TS, Tanzi EL, Lazarus M. The use of fractional laser photothermolysis for the treatment of atrophic scars. Dermatol Surg 2007;33:295-9.
222. Glaich AS, Rahman Z, Goldberg LH, Friedman PM. Fractional resurfacing for the treatment of hypopigmented scars: a pilot study. Dermatol Surg 2007;33:289-94.
223. Batra RS. Surgical techniques for scar revision. Skin Therapy Lett 2005;10:4-7.
224. Alam M, Omura N, Kaminer MS. Subcision for acne scarring: technique and outcomes in 40 patients. Dermatol Surg 2005; 31:310-7.
225. Elson ML. The role of retinoids in wound healing. J Am Acad Dermatol 1998;39(Suppl):S79-81.
226. Mandy SH. Tretinoin in the preoperative and postoperative management of dermabrasion. J Am Acad Dermatol 1986;15:878-9.
227. Hevia O, Nemeth AJ, Taylor JR. Tretinoin accelerates healing after trichloroacetic acid chemical peel. Arch Dermatol 1991; 127:678-82.
228. Leventhal D, Furr M, Reiter D. Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch Facial Plast Surg 2006;8:362-8.
229. Asilian A, Darougheh A, Shariati F. New combination of triamcinolone, 5-fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol Surg 2006; 32:907-15.
230. Pawin H, Chivot M, Beylot C, Faure M, Poli F, Revuz J, et al. Living with acne: a study of adolescents’ personal experiences. Dermatology 2007;215:308-14.
231. Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998;134:454-8.
232. Krowchuk DP, Stancin T, Keskinen R, Walker R, Bass J, Anglin TM. The psychosocial effects of acne on adolescents. Pediatr Dermatol 1991;8:332-8.
233. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999;140:672-6.
234. Yazici K, Baz K, Yazici AE, Kokturk A, Tot S, Demirseren D, et al. Disease-specific quality of life is associated with anxiety and depression in patients with acne. J Eur Acad Dermatol Venereol 2004;18:435-9.
235. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79.
236. Lee IA, Maibach HI. Pharmionics in dermatology: a review of topical medication adherence. Am J Clin Dermatol 2006;7: 231-6.
237. Weiden PJ, Rao N. Teaching medication compliance to psychiatric residents: placing an orphan topic into a training curriculum. Acad Psychiatry 2005;29:203-10.
238. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
239. Renzi C, Picardi A, Abeni D, Agostini E, Baliva G, Pasquini P, et al. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 2002;138:337-42.
240. Baldwin HE. Tricks for improving compliance with acne therapy. Dermatol Ther 2006;19:224-36.
241. Flanders PA, McNamara JR. Enhancing acne medication compliance: a comparison of strategies. Behav Res Ther 1985;23:225-7.
242. Zaghloul SS, Cunliffe WJ, Goodfield MJ. Objective assessment of compliance with treatments in acne. Br J Dermatol 2005; 152:1015-21.
243. McEvoy B, Nydegger R, Williams G. Factors related to patient compliance in the treatment of acne vulgaris. Int J Dermatol 2003;42:274-80.
244. Rasmussen JE, Smith SB. Patient concepts and misconceptions about acne. Arch Dermatol 1983;119:570-2.
245. Tan JK, Vasey K, Fung KY. Beliefs and perceptions of patients with acne. J Am Acad Dermatol 2001;44:439-45.
246. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7.
247. Kellett N, West F, Finlay AY. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne; randomized controlled trial. Br J Dermatol 2006;154:524-32.
248. Pawin H, Beylot C, Chivot M, Faure M, Poli F, Revuz J, Dre´no B. Creation of a tool to assess adherence to treatments for acne. Dermatology 2009;218:26-32.
249. Balkrishnan R, Kulkarni AS, Cayce K, Feldman SR. Predictors of healthcare outcomes and costs related to medication use in patients with acne in the United States. Cutis 2006; 77:251-5.
250. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. The rational clinical examination. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81.
251. Lucero M, Bendeck S, Ramos-Ceballos F, Foster J, Chen SC. Language disparities between patients and dermatologists in describing acne lesions. Dermatol 2007;56:268-73.
252. Del Rosso JQ. A qualitative and quantitative assessment of the application and use of topical acne medication by patients. Cutis 2005;76:109-13.
253. Koo J. How do you foster medication adherence for better acne vulgaris management? Skinmed 2003;2:229-33.